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1.1 Introducing hepatocellular carcinoma
Globally, hepatocellular carcinoma (HCC) is one of the most common
malignancies. HCC mainly develops in relation with chronic liver diseases, e.g
viral hepatitis B and/or C infection, or alcoholic liver disease. Chronic viral
hepatitis B and C frequently progress to liver cirrhosis, which is the end stage
of a diffuse scar formation process in the liver. This process has a profound
impact on the hepatic pathophysiology, leading to serious multiorgan
complications, including portal hypertension, hepatorenal syndrome, and
portopulmonal syndrome. These multiple deteriorating effects and the fact that
cirrhosis related HCC develops in a diseased liver create major limitations to
the therapeutic options for an HCC.
Currently, no curative treatment is available. Surgical resection is an
option in patients who have not developed serious general complications due
to cirrhosis, e.g., those who are still in the early Child stages. A selected
group of patients are eligible for liver transplantation. The selection is based on
the so called Milan-criteria, a scoring system that allows selection of patients
with the least chances for tumor recurrence. Local ablative treatment
modalities, chemoembolisation or radio frequency ablation offers therapeutic
options in selected group of patients depending on tumor size.1-3
Recent developments in molecularly targeted agents have opened new
therapeutic possibilities to treat HCC. Many of these agents, that target growth
factor receptors such as vascular endothelial growth factor receptor (VEGFR),
platelet-derived growth factor receptor (PDGFR), and epidermal growth factor
receptor (EGFR), and consequently interfere with intracellular signaling
pathways downstream of the receptor, have entered phase I/II trials. The
beneficial effects of most these agents are still uncertain. Sorafenib, a
multikinase inhibitor is the first agent that was reported to have significant
effects on halting HCC tumor growth and increasing overall survival in Child-A
cirrhotic patients.4
Most of these molecularly targeted agents are developed to target
molecules involved in angiogenesis. Anti-angiogenic agents are thought to
destroy tumor vascularization, impeding the development of tumor vessels
and/or killing endothelial cells of tumor vessels. Deprived of the necessary
oxygen and nutrients, arrest of tumor growth and death of tumor cells will
follow. Recent evidence from clinical observations suggests that creation of a
situation of stable disease is a more likely outcome of anti-angiogenic drug
treatment, as only immature tumor vessels are affected by therapy. At the
same time, mature tumor vessels will remain functional.5,6 The potential
efficacy of anti-angiogenic treatment in HCC depends on our knowledge on the
angiogenic characteristics of this tumor.
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1.2 The current concept of tumor angiogenesis
The growth of tumor beyond the size of 1-2 mm3 is highly dependent on
new blood vessels formation to keep up with oxygen and nutrients demand
and for removal of metabolites. Several mechanisms for tumor vascularization
have been recognized, including angiogenesis, co-option, endothelial
progenitor cell recruitment, vasculogenic mimicry and mosaic vessels. These
different mechanisms may exist concomitantly in the same tumor or may be
selectively involved in neovessel formation in a specific tumor type.7,8
Angiogenesis, the formation of new vessels from pre-existing ones, is an
important mechanism to explain the formation of new tumor vasculature.9.10
Angiogenic sprouting is one of the mechanisms of neovessel formation to
describe the angiogenic process. It is a complex process and includes
destabilization of pre-existing vessels, proliferation and migration of endothelial
cells, organization of tubular vascular structures, maturation of vessels, and
remodeling of extracellular matrix (ECM). Although by far not all details of the
molecular and cellular mechanisms of angiogenesis have been elucidated yet,
some parts are revealed which are helpful for developing strategies for
anti-angiogenesis therapy and biomarker identification to monitor efficacy of
therapy.
It is now well appreciated that vascular endothelial growth factor (VEGF),
angiopoietins (Ang), and their receptors are important in this process. Ang-2 is
produced and rapidly released by the endothelial cells which will undergo
sprouting. As a consequence, Ang-2 competes with Ang-1 which blocks the
phosphorylation of the Angiopoietin receptor Tie-2. Loss of Ang-1 driven Tie-2
phosphorylation leads to loss of stability of the mature vasculature, and
sensitizes the endothelial cells to growth factors. The destabilized vessels next
progress to the first stage of angiogenic sprouting when VEGF is present.11,12
The growing endothelial cells sprout is guided by a gradient of VEGF-A,
especially the isoforms bound to heparan sulphate, while the shorter isoform
can support the proliferation of endothelial cells. The endothelial cells
migration during angiogenesis involves chemotactic, haptotactic (the
directional migration toward a gradient of immobilized ligands), and
mechanotactic (the directional migration generated by mechanical forces)
stimuli, the degradation of ECM, and cell cytoskeletal remodeling.13 Release of
PDGF-B by the endothelial cells forming new vessels enables recruitment of
PDGF-B receptor expressing pericytes, which leads to endothelial cells
survival and maturation of the new vessels.14
Another variant of angiogenesis exists, which is called intussusceptive
microvascular growth (IMG), in which the insertion of tissue pillars into a vessel
divides a vessel in two. In this process, proliferation of endothelial cells is not
necessary.15 IMG may have roles in additional vascular growth and
development of complex vascular beds after the initial stage of immature
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capillary network formation by sprouting.8,16 In human primary melanoma, a
high IMG, indicated by the number of connections of intraluminal tissue folds
with the opposite vascular wall, is correlated to a high tumor thickness.17
1.3 The concept of vessel co-option
In 1987 Thompson proposed that tumors acquire their vasculature by
incorporation of host tissue capillaries.18 The current concept describes that
there are two models of tumor angiogenesis, one of an avascular tumor
initiation and the other of tumor initiation involving host vessel co-option.11 First
evidence for the latter mode of tumor vascularization was provided by Holash
and colleagues, who showed that in an orthotopic rat C6 glioma model, the
tumor cells exploited the host brain vessels in the initial phases of
tumorigenesis.19
There are also morphological evidences both in experimental models and
in human tumors suggesting that co-option of pre-existing blood vessels might
persist during the entire period of primary or metastasic tumor growth. In 1997,
Pezzella and colleagues studied a series of 500 primary stage I non-small-cell
lung carcinomas, and found in tumors of “alveolar” growth type a preserved
architecture of alveolar septa while the tumor grew in a solid fashion filling the
alveolar spaces without the formation of tumor-associated stroma and new
vessels. So the authors hypothesized that “if an appropriate vascular bed is
available, a tumor can exploit it and grow without inducing
neo-angiogenesis”.20 There is also evidence of absence of angiogenesis in
secondary breast cancer metastasis growth in lung.21
The liver is also a well-vascularized organ with a rich blood supply and
abundant sinusoids. In 1993, Paku et al. studied the morphology of
experimental liver metastases (anaplastic 3LL-HH tumors, Lewis Lung
carcinoma tumor cell lines), and showed during growth of “sinusoidal-type”
tumors that invading cancer cells advanced between the basement membrane
and the endothelial lining of the sinusoids and evoked proliferation of
endothelial cells.22 In liver metastases from patients with colorectal
adenocarcinoma evidence was provided of co-option in one of three growth
patterns, the so-called “replacement” pattern. In this pattern, the reticulin of
liver parenchyma was conserved within the metastases at the tumor-liver
interface. In addition, the endothelial cells of the blood vessels near the
interface in the metastases did not express CD34 and were not surrounded by
mural cells, indicating their similarities with hepatic sinudoidal endothelial cells.
The ratio of the proliferating tumor cell fraction and the proliferating endothelial
cells fraction was 3-4 fold higher in the replacement-type metastases
compared with the other metastases.23
Paku et al. described a mechanism for the development of the vasculature
in “pushing-type” liver metastasis of experimental colorectal cancer.24 It
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includes the proliferation of smooth muscle actin-positive stellate cells and the
formation of vascular lakes from the fusion of the sinusoids at the surface of
the tumor, and the development of vessel-containing connective tissue
columns that traverse the tumor.
1.4 Parameters used to measure angiogenesis
As anti-angiogenic therapy is a promising treatment for human solid
tumors, evaluation of the status of angiogenesis in tumors can be used in
selecting patients for anti-angiogenic therapy and in selecting the appropriate
type of anti angiogenic therapy for the individual patient.
For basic cell biological studies aimed to unravel the molecular control of
angiogenesis, a number of experimental assays are available. For example,
endothelial cells can spontaneously form tubes when cultured in gelatin in vitro,
and many in vitro assays based on this behavior have been designed after the
first observation.25,26 In these in vitro assays and in some in vivo assays, such
as the corneal micropocket, direct observations of angiogenesis processes are
optional, e.g. by digital photograph and quantification of capillary sprout length.
These assays are crucial tools for the research on therapeutic agents that can
inhibit or promote angiogenesis which can in the future be used in clinical
settings.
However, in tumor tissues from patients it is impossible to observe the
angiogenesis associated cellular and molecular processes directly, as biopsies
represent a static moment at an unknown time point after tumor growth
induction and angiogenic switching. Yet a number of features can be assessed
in these biopsies in daily histopathological practice, which indirectly can
provide clues on the vascular status of a tumor. For example, one can
quantitate intratumoral microvessels, measure structurally aberrant tumor
vessels, and assess the production of pro-angiogenic and anti-angiogenic
factors. So far no validated biomarkers of angiogenesis or efficacy of
antiangiogenesis therapy are available for routine clinical use.27
1.4.1 Quantification of intratumoral microvessels
Parameters to quantify vessels in cancer include microvascular density
(MVD), total microvessel area (TVA, including Chalkley counts), and vascular
branching counts.28,29 MVD in histological sections of human tumors was for a
long period of time regarded as a representation of the status of angiogenesis.
However, despite its wide application in many studies, it was soon recognized
that although MVD counts can assess the presence of blood vessels, it does
not give an indication of the degree of angiogenesis, as the dynamics of vessel
formation are not determined. Still, assessment of the MVD is useful as a
prognostic factor in some human cancers,30,31 although it should be realized
that it is not per se a good measurement of the efficacy of anti-angiogenic
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therapies.32 As pointed out by Folkman and colleagues several years ago,
MVD largely reflects the metabolic burden of the supported tumor cells.33
Two categories of endothelial cells-specific markers are used to highlight
intratumoral vessels for quantitative MVD analysis. The pan-endothelial cells
markers such as CD31, CD34, and vWF can be visualized in formalin-fixed
tissue. Because of its robustness and ease of use, CD34 is now considered
the optimal marker.28 Other markers which indicate vascular differentiation and
activation, and which can be visualized in frozen tissues, include CD105
(endoglin), Tie2, integrin v3 and the complex of VEGF and VEGFR-2.
Quantification of vessels can be done by microscopy, manually or by
computer assisted systems. Generally, vessels in 3 “hot spots” (defining the
most vascularized areas of the tumor) are measured. The rationale of counting
microvessels in “hot spots” is that these areas originated from tumor cell
clones with the highest angiogenic potential and consequently, with the easiest
access to the blood stream and with an increased probability of metastasis.34
Not all researchers use “hot spots”, some measure in random areas and some
use computerized scanning of the tumor as a whole in one section.35-37 Of all
these methods major drawbacks are that they are difficult to standardize, that
tumor heterogeneity is not easily taken into account, and that they are prone to
reader-dependent variability.
The Chalkley point overlap technique has been used as an estimation of
relative microvascular areas, in which a 25-point Chalkley eyepiece graticule is
applied to each hotspot. The graticule is oriented to allow it to hit the maximum
number of points of interest. The Chalkley count is taken as the mean value of
three hotspots. By this technique, observers do not need to make decisions
whether two immunostained and adjacent structures were the reflection of one
single or two separate blood vessels.34 Chalkley counts have been suggested
as the primary method for immunohistochemical evaluation of angiogenesis,
because of better reproducibility and correlation with prognosis.38-40
1.4.2 Assessment of structurally aberrant tumor vessels
The structure of tumor vessels differs from normal vessels. Size- and
shape-related parameters, microvascular shape and complexity are used to
measure the abnormality of vessels.29
Mature vessels are covered by pericytes and have a basement membrane
lining. The percentage of endothelial cells with a pericyte or basement
membrane coverage can hence be used as a surrogate of vessel maturity.28
Numerous studies use double immunohistochemical staining to colocalize
endothelial cells and pericytes with an antibody for endothelial cells and
another one for pericytes. Endothelial cells markers have been discussed
above, while pericyte markers generally used include -smooth muscle actin
and desmin.41,42
Through confocal laser scanning microscopy on immuno-fluorescence
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slides or normal light microscopy on immunohistochemistry slides of
paraffin-embedded tissues, 3-dimensional reconstruction techniques can
reveal an extensive and complex network of microvasculature of tumor and
offer a useful tool to examine the spatial relationship between different
components in the tumor tissues.43,44 But the time-consuming nature together
with the need for specialized equipment hampers its widespread application in
daily histopathological practice.
1.4.3 Quantification of endothelial cells proliferation and apoptosis
Compared to MVD, changes in endothelial cells apoptosis and
proliferation status may more accurately reflect whether tumor-associated
blood vessels regression and remodeling is taking place. Double-label
immunohistochemical staining with two antibodies, one for identifying
endothelial cells and the other for indicating proliferation (such as anti-ki-67,
anti-PCNA) is applicable on paraffin-embedded human cancer tissue, and can
show the proliferative fraction of tumor cells and endothelial cells
simultaneously.45 And also on paraffin sections double-label staining with
antibodies to detect endothelial cells and apoptosis (anti-active caspase 3)
reveals apoptosis of endothelial cells and tumor cells simultaneously.34
1.4.4 Pro-angiogenic and anti-angiogenic factors, proteolytic enzymes
Other parameters used in the research field of tumor angiogenesis are
quantification of angiogenic growth factors, anti-angiogenic factors and
proteolytic enzymes, using various technologies including
immunohistochemistry, western blot, ELISA, and quantitative or
semi-quantitative RT-PCR. Zymography can be used to measure the matrix
metalloproteinases (MMPs) activation. The related factors usually detected
include VEGF and receptors, angiopoietins, fibroblast growth factors (FGFs),
MMPs, urokinase-type plasminogen activator (uPA).
Measuring circulating or urinary levels of angiogenic growth factors is another
approach thought to reflect the angiogenic status of tumor.5,46 The
pre-treatment circulating levels of VEGF, bFGF and PDGF furthermore
predicted patient survival in a number of studies.47,48 They are easy to
standardize and reproduce, but release of many growth factors from platelets
and other cells may hamper the clinical relevance of these measurements.49,50
In recurrent glioblastoma patients treated daily with AZD2171 (a pan-VEGF
receptor tyrosine kinase inhibitor), plasma bFGF and stromal cell-derived
factor 1 (SDF1) levels increased with the tumor escaping treatment
concomitantly.51 Soluble VEGF receptors such as VEGFR1, VEGFR2 and
VEGFR3 are currently being investigated in a variety of cancer indications.
More work is still needed to ascertain whether these biomarkers can predict
patient survival or response to anti-angiogenic therapies.52,53
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1.5 Angiogenesis in various tumors
Several methods are nowadays available for the histopathologist to
establish the vascular dynamics of a tumor on the tissue level. Yet, one should
realize that tumor angiogenesis is heterogeneous in phenotype and that the
concomitant microvascular heterogeneity exists at different levels, i.e., among
different tumor types, in different developmental stages of tumor growth, and
even within the same tumor or within the same tumor vessel segment.54 The
mode of angiogenesis might also be influenced by the specific vascular
characteristics of the organs in which the tumor develops.
Due to the lack of a clear definition, uniform criteria, and methods to
assess the angiogenic status of a tumor, it is hard to compare the angiogenic
activity of different types of tumors and define the precise angiogenic status of
a tumor. Still, with the above described toolbox scattered studies have tried to
give more insight in the matter. For example, a study in six types of different
human tumors (glioblastomas, renal cell carcinoma, colon carcinomas,
mammary carcinomas, lung carcinomas, and prostate carcinomas) showed
high MVD phenotype in the different tumors, with glioblastomas and renal cell
carcinoma having the highest average MVD. Proliferating capillary index (the
ratio of the number of microvessels with proliferating endothelial cells and the
total number of microvessels) was significantly different between the tumors,
with glioblastomas 9.6±6.1%, renal cell carcinoma 9.4±5.2%, colon
carcinomas 7.8±5.2%, mammary carcinomas 5.0±4.8%, lung carcinomas
2.6±2.5% and prostate carcinomas 2.0±1.4%. Microvessel pericyte coverage
index also varies, with glioblastomas 12.7±7.9%, renal cell carcinoma
17.9±7.8%, colon carcinomas 65.4±10.5%, mammary carcinomas 67.3±14.2%,
lung carcinomas 40.8±14.5%, and prostate carcinomas 29.6±9.5%.55 From
this study, we can see that each human tumor type presents itself with its own
set of features of vascularization status, and glioblastomas and renal cell
carcinoma had higher MVD and proliferating capillary index, and lower
microvessel pericyte coverage index compared to other 4 tumors.
1.6 The aims of the studies described in this thesis
Angiogenesis is considered the most important mode of tumor growth
associated neovascularization to support tumor growth and hence an
interesting target for therapy. Yet, for HCC much remains to be elucidated
regarding the angiogenic status and the consequent putative suitability of the
various types of anti-angiogenic treatment options. Due to the unique status of
vascularization of the liver it is conceivable that angiogenesis in the liver may
follow a different mode than in other organs. First, the liver has a dual blood
supply provided by the portal vein and hepatic artery. Second the liver is a well
vascularized environment created by the hepatic sinusoids which are lined by
Chapter 1
17
hepatic sinusoidal endothelial cells. These cells differ from vascular endothelial
cells in that they are fenestrated and that there is no basement membrane
coverage, to ensure optimal exchange possibilities between blood and
hepatocytes.
Based on these unique vascular characteristics in the liver we embarked
on this thesis project to investigate several aspects of vascular changes and
angiogenic features in primary hepatic tumors, both malignant and benign. It is
well known that the sinusoidal endothelium in HCC and benign hepatic tumors
undergo phenotypic alterations, e.g. expression of CD34 and coverage by
alpha smooth muscle actin positive cells. In both tumor types there is also the
presence of abnormal vessels, the so called solitary arteries in HCC and
hepatic adenoma and thick walled arteries in focal nodular hyperplasia.
Whether these vascular changes resulted from angiogenesis following the
pathways described before is not well documented on the tissue level.
Therefore we addressed the following issues:
1) The angiogenic status of HCC as defined by MVD, vascular maturation, and
endothelial cell proliferation and apoptosis, to enable to detect a possible
correlation between these characteristics and the pattern of HCC
vascularization assessed by diagnostic imaging and prognosis (chapter 2)
2) The molecular status of angiogenesis in HCC and benign liver tumors. We
investigated the balances in gene and protein expression levels of members of
the VEGF and Angiopoietin/Tie-2 system that are considered to be directly
responsible for controlling angiogenic sprouting of blood vessels. (chapters 3
and 4)
3) COX-2 expression and its putative relation with angiogenesis in HCC.
COX-2 was demonstrated to be related with tumor angiogenesis in several
types of tumors with consequent therapeutic implications regarding the
application of COX-2 inhibitors. (chapter 5)
By this means we tried to gain insight in the angiogenic status of primary
hepatic tumors both morphologically and on the molecular level, in relation with
clinical characteristics. Apart from providing new pathogenetic insight the new
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Abstract 
Background: Sorafenib is an effective treatment of hepatocellular carcinoma 
(HCC) in patients with liver cirrhosis. It might also be effective in non-cirrhotic 
HCC provided that angiogenic properties of both tumor types are comparable. 
The aim of this study is to compare endothelial cell dynamics, microvessel 
density (MVD) and vessel maturation as indirect markers of angiogenesis in 
human HCC in cirrhotic and non-cirrhotic livers. 
Methods: CD34 was applied to identify tumor microvessels, double 
immunolabeling Ki67/CD34 and activated caspase-3/CD34 to assess 
endothelial cell proliferation and apoptosis and α-smooth muscle actin/CD34 
for pericyte coverage. These characteristics were compared in cirrhotic (n = 33) 
and non-cirrhotic HCCs (n = 37). 
Results: Microvessels in cirrhotic and non-cirrhotic HCC were mainly mature. 
In both groups endothelial cell turnover was low and MVD was not different. 
There was no correlation between MVD and venous invasion, tumor size and 
turnover of tumor cells or endothelial cells. MVD was negatively correlated with 
contrast wash out in the portal venous phase of CT scanning. In transplanted 
patients MVD was not correlated with survival, whereas in patients after liver 
resection a high MVD was associated with a better prognosis. 
Conclusion: Angiogenic characteristics of HCC in cirrhotic and non-cirrhotic 
liver have a remarkable similarity. 
Key words: angiogenesis, sprouting, endothelial cell proliferation, apoptosis, 
pericyte, hepatocellular carcinoma 
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Introduction 
Hepatocellular carcinoma (HCC) generally develops in cirrhotic liver. The 
various underlying chronic liver diseases that result in cirrhosis have a variable 
incidence of HCC development.(1) Viral hepatitis B and C (HBV, HCV) are 
world-wide among the most frequent causes of HCC. However, also other 
chronic liver diseases like alcohol induced cirrhosis or hemochromatosis are 
associated with HCC. The risk of developing HCC is highly dependent on the 
epidemiology of viral hepatitis and alcohol consumption.(2) The chronic 
inflammation in the cirrhotic liver induces architectural and functional changes 
which result in hypoxia which is one of the most potent stimuli for 
angiogenesis.(3) HCC develops very rarely in patients with normal liver 
histology (thus without liver cirrhosis) and without underlying viral hepatitis. In 
contrast to patients with HCC in cirrhotic livers, patients with non-cirrhotic HCC 
often present in advanced stages because they are not participating in 
screening programs. Additionally, they often do not qualify for liver 
transplantation because of the large size of the tumors. Recurrence rates up to 
40% after partial liver resection are reported.(4)
HCC is a highly vascularized tumor and has a predominant arterial supply 
which can be demonstrated by contrast enhanced CT scanning or angiography, 
in which hyperattenuation is obtained in the arterial phase and hypoattenuation 
in the portal phase.(5) Arterial hypervascularization is one of the diagnostic 
criteria of HCC in cirrhotic patients.(6) It is assumed that hypervascularization 
as seen on imaging techniques correlates with angiogenesis.(7)
Angiogenesis is characterised by destabilisation of existing vessels, 
endothelial cell proliferation, and vessel sprouting, followed by stabilisation of 
the newly formed vessels.(8) Because of this many antiangiogenic treatments 
target VEGF which is a crucial growth factor for endothelial cell proliferation.(9)
The recently published results of the SHARP trial demonstrate a nearly 3 
months survival advantage in cirrhotic patients with HCC treated with 
sorafenib.(10) One of the working mechanisms of sorafenib is inhibition of 
neoangiogenesis by inhibition of the vascular endothelial growth factor 
receptors (VEGFR).(11) In countries with a low incidence of viral hepatitis the 
relative proportion of patients with non-cirrhotic HCC is significantly higher and 
thus a relevant clinical entity. It is unknown whether HCC in non-cirrhotic liver 
has similar angiogenic aspects as HCC in cirrhotic liver. Similarities between 
angiogenic characteristics of HCC in cirrhotic and non-cirrhotic liver could lend 
support to sorafenib treatment of advanced HCC in non-cirrhotic patients. 
Therefore, the aim of the present study was (1) to compare the angiogenic 
status in HCC in cirrhotic and non-cirrhotic liver and (2) to correlate MVD with 
tumor, patient and radiological characteristics of HCC. To this end we 
analysed the dynamics of endothelial cells in tumor vessels in HCC by 
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quantification of MVD, the apoptotic and proliferation rate of endothelial cells in 
tumor microvessels, and the tumor vessel coverage by pericytes, which is 
considered to be a sign of mature vessels. 
Patients and methods 
Patients 
All procedures and use of (anonymised) tissue were performed according 
to recent national guidelines. A total of 70 HCC tumor specimens from 69 
consecutive patients were retrieved from the files of the department of 
pathology. In 31 cases HCC developed in cirrhotic livers and these patients 
underwent a liver transplantation (n = 30) or a local resection (n = 1). The 
causes of cirrhosis were HBV (n = 8) or HCV (n = 9), cryptogenic (n = 5), 
primary biliary cirrhosis, alcohol, autoimmune hepatitis, 1-antitrypsin 
deficiency (n = 2 each), and biliary atresia (n = 1). In two additional patients 
with a cirrhotic liver, biopsies of the HCC were available for analysis. In the 30 
liver explants solitary tumor nodules were found in 13 cases, 2 nodules were 
found in 8 cases, 3 nodules in 3 cases and the remaining 6 cases had more 
than 3 nodules. A representative sample of one nodule per case was obtained 
for the analysis. Another 35 cases developed HCC in normal, non-cirrhotic, 
non-fibrotic livers and in none of these patients HBV or HCV antibodies were 
detectable. All these patients underwent a partial liver resection. In one patient 
a recurrent HCC in a non-cirrhotic liver was resected 16 months after a 
previous local resection and both tumors were included in the study. The follow 
up of this patient was calculated from her first operation. A tumor biopsy of 
another non-cirrhotic patient was added for analysis. In the non-cirrhotic group 
29 patients had single tumor nodules. The remaining 6 patients had more than 
one tumor nodule and in those cases a representative sample of one tumor 
nodule per case was obtained for the analysis. None of the patients underwent 
previous treatment for HCC. Five out of the 35 non-cirrhotic patients were 
excluded from the survival analysis because of early (within 3 months) 
postoperative mortality (n = 3) or because of non-curative resections (n = 2). 
Two of the 30 transplanted patients were excluded because of early 
postoperative mortality. The follow up of patients consisted of 3 monthly 
alpha-fetoprotein serum levels, thoracic X-rays and ultrasound examinations of 
the liver remnant during the first 2 years after partial liver resection and 
6-monthly thereafter until 5 years after the resection date. In case of suspicious 
findings, CT scan of thorax and abdomen were performed in order to detect 
resectable recurrences. In case of unresectable recurrences patients were 
treated with best supportive care. In patients after liver transplantation routine 
follow-up was according to our protocol, including 6 monthly ultrasound of the 
liver, alpha-fetoprotein serum levels and thoracic X-rays. 
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Immunohistochemistry 
4 Dm serially cut paraffin sections were used for immunohistochemical 
staining with CD34 (clone Qbend 10, ready to use dilution, Immunotech 
Marseille, France), Ki 67 (DAKO, Glostrup, Denmark. 1:75) and anti-cleaved 
caspase-3 (Cell Signaling Technology, Danvers, MA, USA, 1:50). Single 
immunostaining with anti-CD34 was performed to detect MVD in the tumors. In 
short, after deparaffinization and blocking of endogenous peroxidases sections 
were incubated with CD34 for 1 hour at room temperature, followed by the 
second antibody (dilution 1/50) and diaminobenzidin (DAB) to develop the 
staining reaction and nuclear counterstaining with hematoxylin. Double 
immunostaining of anti-CD34 and anti-cleaved caspase-3 were performed as 
described previously.(12) Double immunostaining using anti-CD34 and 
anti-Ki67 was performed after antigen retrieval in a microwave with Tris/EDTA 
buffer (pH 9) for 15 minutes. Sections were incubated with anti-Ki67 for 1 hour 
at room temperature, followed by RAMPO/GARPO and DAB to develop the 
staining reaction. Sections were then washed in a glycin/HCl solution (pH=2) 
for 45 minutes and incubated with anti-CD34 for 1 hour at room temperature. 
GAMAP and Fast Red were used for the staining reaction and hematoxylin for 
nuclear counterstaining. Double immunostaining of CD34 and SMA was 
performed to detect vascular pericyte coverage in a similar method as the 
CD34/Ki67 double labeling but without prior antigen retrieval. 
Evaluation of immunohistochemical staining 
Grading of HCC was done according to Edmondson and Steiner and the 
growth patterns were identified as trabecular, acinar, solid, and scirrhous. The 
chalkley point overlap morphometric technique was used for quantification of 
MVD at three “hot spots” on CD34-stained sections, as described previously (12, 
13). First, tumors were scanned at low magnification to identify areas with high 
MVD (“hot spots”). Then, at a magnification 200, an eyepiece graticule 
containing 25 randomly positioned dots was rotated to reach the maximum 
number of points overlapping with a CD34 positive structure, being the vessels 
in the vascular hot spot. The number of overlaying dots was counted SMA 
coverage of vessels was calculated as thenumber of dots within or on the 
SMA positive vessels as the percentage of the total number of dots 
overlaying CD34 positive structures. On CD34 / Ki67 double stained sections, 
Ki67 labeling was determined in a 400 microscopic field, at the same three 
“hot spots” as used for MVD counting. The vascular Ki67 labeling index (LI) 
was defined as the number of Ki67+/CD34+ endothelial cell nuclei per total 
number of endothelial cells counted. Ki67 LI of tumor cells was obtained by 
counting Ki67 positively stained tumor cells per 300 individual tumor cells in 
each area. On CD34/activated caspase-3 double labeled sections, the 
activated caspase-3 positive HCC cells and activated caspase-3 positive 
endothelial cells were calculated in three “hot spots” at 400 magnification. For 
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each case, an apoptotic index (AI) was calculated as the number of apoptotic 
cells100/number of high-power fields. 
Analysis of CT images 
Images were analyzed using the change in attenuation of dynamic 4-phase 
CT scanning during the arterial and portal phase of contrast enhancement. 
Only source data of CT scans performed after 2002 were available for analysis. 
The enhancement (in Houncefield units; HU) in the tumor and the surrounding 
parenchyma was recorded. In tumors with a heterogeneous enhancement the 
most hyperattenuating region was identified in order to get the most reliable 
comparison with MVD, which was scored in the vascular hot spot. The relative 
enhancement of the tumor was compared to that of the surrounding 
parenchyma in the arterial and portal phase according to the equation: 
Relative Enhancement = HU tumor – HU parenchyma x 100% 
HU parenchyma 
The relative enhancement was correlated with MVD. We chose for 
calculation of the relative enhancement to eliminate interindividual differences 
in contrast medium enhancement in HCC tumor nodules versus the adjacent 
parenchyma. This difference is highly dependent on various factors including 
patient’s physiology –e.g. cardiac output in the hyperdynamic circulation of 
cirrhotic patients.(14)
Statistics 
Comparisons of the vascular dynamics in cirrhotic versus non-cirrhotic 
HCCs were performed using non-parametric testing (Mann Whitney test). The 
results are presented as median values with inter quartile ranges (IQR). 
Analysis of MVD in relation to tumor grade was done using ANOVA. 
Categorical variables were analyzed using the Chi-square test or the Fisher 
exact test where appropriate. Survival analysis was performed using the 
Kaplan Meier method with the log rank test for comparisons. Median survival 
and 95% confidence intervals (CI) are given together with 5-year survival data. 
Pearson correlation coefficients are presented for data with a normal 
distribution. Variables with a non-parametric distribution were log transformed 
in order to normalize the data. 
Results 
Endothelial cell apoptosis and proliferation are rare events in tumor 
microvessels 
In 31 of the 37 non-cirrhotic HCCs and 29 of the 33 cirrhotic HCCs no 
apoptotic endothelial cells were identified. In the remaining tumors apoptotic 
endothelial cells could rarely be identified (Figure 1). Endothelial cell 
proliferation was also rare in both types of HCC (figure 2). Nevertheless, the  
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Table 1. Angiogenic and survival characteristics in patients with HCC in non-cirrhotic 
versus cirrhotic livers. 
 Non-cirrhotic HCC Cirrhotic HCC P-value 
Endothelial cell Proliferation 0.03 (0.04) 0.02 (0.02) 0.011 
MVD 13.0 (6.0) 11.3 (3.0) 0.46 
MVD mean (range) venous 
invasion  





% mature vessels 79.0 (61.0) 63.0 (46.0) 0.27 
% tumor cell proliferation 5.8 (15.1) 5.0 (8.4) 0.23 
Apoptotic tumor cells 0.33(1.33) 0.0 (0.67) 0.09 
Median survival months (95% CI)









Numbers represent median values (interquartile range) unless stated otherwise.
median number (IQR) per high power field in non-cirrhotic HCCs was higher 
than in cirrhotic HCCs (Table 1, p = 0.011). 
Similar MVD in HCCs in cirrhotic versus non-cirrhotic livers 
CD34 positive tumor vessels demonstrated a rather uniform pattern of 
staining. A striking change in CD34 expression was visible at the interface of 
an HCC and the surrounding normal parenchyma (figure 3). In the 
parenchyma sinusoids were faintly stained with a progressive increase in 
staining intensity towards the tumor. Of note is the change in morphology, with 
the sinusoids in the normal liver demonstrating obvious lumina, whereas in the 
tumor itself the vessel lumen was often slit like and the vessels were tortuous 
when a sinusoidal-like pattern is present. Quantification of MVD revealed no 
difference between non-cirrhotic and cirrhotic HCCs (table 1) 
MVD in relation to vascular invasion 
Because vascular invasion is an important adverse prognostic variable, 
MVD was compared in tumors with vascular invasion versus those without 
vascular invasion in cirrhotic and non-cirrhotic livers separately. The mean 
MVD in cirrhotic HCCs was comparable in tumors with versus those without 
vascular invasion (table 1). In non-cirrhotic livers, tumors without vascular 
invasion tended to have a lower MVD as compared to tumors with vascular 
invasion, but without reaching statistical significance (p = 0.07, table 1). 
The majority of tumor microvessels are covered by SMA positive cells 
Microvessels which are double positive for CD34 and SMA were 
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Table 2. Baseline characteristics of the non-cirrhotic versus the cirrhotic patients with 
HCC included in the survival analysis.
Clinicopathological  Non-cirrhotic  Cirrhotic patients p-value
Characteristic patients (N = 30)  (N = 28)  
Gender Male : female 16:14 25:3 0.001 
Treatment    
-transplantation  28  
-right/left hemihepatectomy 12/7  <0.0001 
-extended right hepatectomy 4   
-local excision 4   
-2 or 3 segment resection 3  
Age: mean (SD) 58.9 (14.9) 50.2 (17.9) 0.06 
Range 19.6 – 82.9 1.5 – 68.1 
No. of tumor nodules:    
1 / 2-3 / >3 26/2/2 8/10/10 <0.0001 
Size of largest tumor    
Median (range) 13.0 (3.0 – 25.0) 2.7 (1.0 – 6.0) <0.0001
Alpha fetoprotein 6.8 21.5  
Median (range) (3 – 93,933) (2– 16,000) >0.6
CD34+/SMA+ vessels in non-cirrhotic and cirrhotic HCCs was comparable 
(table 1). These numbers suggest that the majority of HCC microvessels are 
stabilized, quiescent vessels. 
Proliferation and apoptosis in tumor cells 
Proliferation rate of tumor cells in non-cirrhotic versus cirrhotic HCCs was 
not different (table 1). The rate of apoptotic tumor cells in general was low, 
despite the fact that they could be easily identified if present (figure 1). The 
median number of apoptotic tumor cells per high power field in non-cirrhotic 
livers was not different from that in cirrhotic livers (table 1). 
MVD in relation to tumor and endothelial cell characteristics 
Of the 70 HCCs, 6 were graded as (Edmonson Steiner) grade 1, 39 grade 
2, and 25 grade 3. ANOVA with post hoc comparisons revealed a significant (p 
< 0.05) difference between MVD in grade 1 (mean 9.4 SD 2.8) versus in grade 
2 (mean 13.1 SD 3.4) HCCs. 
MVD was not correlated with tumor size, the rate of tumor cell proliferation 
or apoptosis, and the rate of endothelial cell proliferation or apoptosis in tumor 
microvessels. Also no correlation was encountered between MVD and the 
number of SMA positive CD34 positive microvessels (mature vessels). 
MVD is negatively correlated with contrast wash out but is not correlated 
with contrast supply 
The correlation between MVD and radiological enhancement of the tumor 
in relation to the surrounding parenchyma (relative contrast enhancement) was 
30
                                                                       Chapter 2
31
analyzed during the arterial and portal phase of CT scanning. In general the 
tumors were hyperintense in the arterial phase; the mean number of HU in the 
tumor was 17 % (range -56 to +57%) higher as compared to the surrounding 
parenchyma. No correlation (r = -0.23, p =0.52) was found between MVD and 
the relative contrast enhancement of the tumor during the arterial phase. In the 
portal phase most of the tumors were hypointense; the mean number of HU 
was 15% (range -35% to +19%) lower than the surrounding parenchyma. A 
negative correlation (r = -0.75, p = 0.012) was found between MVD and the 
enhancement of the tumor in the portal phase. Thus, the higher the MVD in the 
tumors the less contrast was present in the tumor during the portal phase of 
contrast enhancement. 
MVD and patient survival 
First we analyzed survival in cirrhotic and non-cirrhotic patients separately 
because of the major differences in patient and disease characteristics in the 
two groups (table 2). Only two non-cirrhotic patients received a liver transplant 
because of recurrent HCC in the remnant liver after partial liver resection. 
These two patients were categorized as resection patients according to their 
initial treatment. Survival in transplanted patients was better than in resected 
patients (p = 0.036) with a median survival of 112 months (95% CI: 60 – 165 
months) and 38 months (95% CI: 11 – 65 months) respectively. Five-year 
survival rates were 66.8% in transplanted and 44.3% in resected patients. 
MVD was categorized in “low” (< median MVD value) and “high” values (> 
median MVD value). Survival in transplanted patients was not different in the 
low versus the high MVD values with a median survival of 112 months (95% 
C.I 45.2 – 179.8) in the low MVD group (figure 4). Median survival in the high 
MVD group was not reached. In contrast, in the resection group, the median 
survival in patients with tumors with a high MVD (58 months, 95% CI: 24.8 – 
90.7 months) was longer (p = 0.05) as compared to the median survival in 
patients with low MVD tumors (12.2 months, 95% CI: 5.4 – 19.0 months, figure 
4).
Discussion 
The recently published survival advantage of anti angiogenic treatment 
with sorafenib of HCC in cirrhotic patients may offer new treatment options for 
HCC in non-cirrhotic patients. They often have a graver prognosis because of 
the more advanced stage of disease at presentation because these patients 
do not participate in surveillance programs. Liver transplantation is often 
precluded because of the large size of the tumor at presentation and the 
recurrence rate after partial liver resection is high. The aim of the present study 
was to perform a comparative analysis of the angiogenic characteristics of 
HCC developing in cirrhotic and non-cirrhotic patients. Therefore we analysed 
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angiogenesis at three different levels; quantification of proliferation and 
apoptosis of endothelial cells in tumor vessels at the cellular level, 
quantification of MVD at –tumor- tissue level and analysis of tumor 
vascularisation as seen by contrast enhanced CT imaging. The main 
conclusion is that the angiogenic characteristics of HCC in cirrhotic livers are to 
a large extent similar to those in non-cirrhotic livers. Additionally, microvessels 
in both tumor types exhibit a very low turnover status and mainly have 
characteristics of stable mature vessels. Indirect evidence of angiogenic 
activity could be provided by endothelial cell dynamics, e.g. proliferative 
activity and apoptosis. Our findings of a low proliferative and low apoptotic rate 
in endothelial cells, the presence of a high SMA coverage rate and the 
absence of a positive correlation between hypervascularity on imaging and 
tumor MVD, are compatible with a rather stable endothelial cell compartment 
in tumor vessels in HCCs irrespective of the presence of cirrhosis. These 
results are in agreement with the findings of our previous study in which we 
quantified gene and protein expression of VEGF-A, its receptors VEGFR-1 and 
VEGFR-2 and the angiopoietin/Tie 2 system in HCC of cirrhotic and 
non-cirrhotic patients.(15) We found no increase in VEGF-A levels, nor the 
characteristic pattern of increased angiopoietin-2/Tie-2 concomitant with 
decrease of angiopoietin-1 which is the usual profile of tumor angiogenesis as 
seen in highly angiogenic tumors, e.g. renal cell carcinoma.(15)
Although angiogenic sprouting, new capillary bud formation from pre-existing 
vessels, was initially thought to be the main mechanism of new vessel 
formation, various other mechanisms of vascularisation of tumors were put 
forward.(16) Especially for an extremely rich vascularized organ like the liver, 
the process of cooption of pre-existent vessels – sinusoids- might be a suitable 
option.(17) Cooption is a process in which the tumor is hijacking (coopting) 
pre-existent vessels of the host organ or tissue to obtain vascularisation for 
ongoing tumor growth, and has been demonstrated in metastatic brain tumors 
in mice.(18) A progressive increase in CD34 expression by hepatic sinusoidal 
endothelial cells parallels the progression from low grade to high grade 
dysplastic nodules into frank HCC.(19) This increased expression is considered 
to be a sign of angiogenesis.(7, 20-23) Another possibility however is that 
changes in the environment (from normal hepatocytes to (pre)malignant cells) 
induce an altered phenotype of endothelial cells. In other words, increasing 
CD34 expression on endothelial cells might represent a bystander effect of 
changing influences from adjacent cells or growth factors. This was 
demonstrated for instance also for CD31 expression; co-cultures of sinusoidal 
endothelial cells with hepatocytes or stellate cells or administration of VEGF 
maintained the highly differentiated state of CD31 negative sinusoidal 
endothelial cells, whereas absence of VEGF resulted in CD31+ 
dedifferentiated sinusoidal endothelial cells.(24) The altered phenotype of 
sinusoidal cells to CD34 and CD31 expressing tumor endothelial cells and  
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demonstrating apoptosis in 
tumor microvessels. Apoptotic 
endothelial cell (black arrow) 
within tumour microvessel as 
shown by double 
immunolabeling with anti CD34
(red) and anti activated 
caspase 3 (brown). Negative 
endothelial cell nucleus is also 
visible (blue arrow). An 
example of an apoptotic tumor 





demonstrating proliferation in 
tumor microvessels. Double 
immunolabelling with CD34 
and Ki67 of a hepatocellular 
carcinoma. Endothelial cells 
are stained with CD34 (red) 
and nuclei of proliferating cells 
with Ki67 (brown). Proliferating 
endothelial cells (arrow) and 
proliferating tumor cells (arrow 
head) are clearly visible. 
Figure 3. Immunolabelling with 
CD34 (brown), staining the 
border of a hepatocellular 
carcinoma with adjacent 
non-tumorous liver parenchyma. 
The adjacent liver parenchyma 
(lower right hand corner) shows 
a very faint staining with a 
gradual increase in staining 
intensity towards the tumour 
(upper left hand border). 
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Figure 4. Overall survival of patients with HCC in non-cirrhotic liver after partial 
hepatectomy (left panel) or patients with HCC in cirrhotic liver after liver transplantation 
(right panel) stratified according to microvessel density (MVD). MVD is divided in values 
above and below the median value. Only patients without post operative mortality and 
potentially curative liver resections are included in this analysis. 
increased presence of pericytes coverage, along with the absence of 
VEGF-A/angiopoietin driven sprouting angiogenesis are compatible with 
vascular remodelling rather than sprouting angiogenesis. 
Our finding of a more favorable survival of patients with high MVD tumors 
after partial liver resection is in agreement with the results of Nanashima(25),
but opposite to the findings of others, who found a worse prognosis in patients 
with tumors with high MVD (table 3). Several important differences exist 
between our patients and the series presented in table 3. Firstly, our resected 
patients were all non-cirrhotic and HBV and HCV negative, which is in contrast 
to all other series reporting on patients with cirrhotic livers with positive 
hepatitis serology. Secondly, clinicopathological characteristics of HCC in the 
West (our series) and the East (all other series) are different.(26) Finally, the 
proportion of patients with HBV or HCV related HCC in the various study 
populations can influence the results because MVD in HCCs in HCV positive 
patients is higher than in HBV positive patients.(27)
Conflicting results have been published on the correlation between 
hypervascularity on contrast enhanced CT and MVD in HCC. In one study a 
correlation between MVD and arterial and portal phase contrast enhancement 
was found,(28) whereas others found no correlation.(29, 30) We did not find a 
positive correlation between the relative contrast enhancement in the tumor in 
the arterial phase and MVD. However, a negative correlation between contrast 
in the tumor in the portal phase and MVD was found. These findings suggest 
that a high MVD is more associated with rapid wash out of contrast, than with a 
large arterial blood supply. 
We found a remarkable difference in the relation of MVD on survival; no  
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NE: not evaluated; (1) Type of treatment for HCC. RES: partial liver resection; LT: liver 
transplantation; (2) Antibody used for detection of microvessels. vWF: anti-von Willebrand 
factor (factor VIII); CD34: anti-CD34 antibody; CD105: anti-CD105 antibody; (3) Prognosis 
of patients with tumors with high MVD as compared to those with low MVD. DFS disease 
free survival; OS overall survival; (4) Correlation of hypervascularity as seen on contrast 
enhanced CT or angiography with MVD. +/-/0: positive, negative or no correlation; (5) 
Correlation of vascular endothelial growth factor (VEGF) with MVD. +/-/0: positive, 
negative or no correlation
effect was found in patients after liver transplantation, whereas patients with a 
HCC with a high MVD had a better prognosis after partial liver resection than 
those with a low MVD. A possible explanation for the fact that MVD does not 
relate to survival in transplanted patients could be that most frequently 
metastases first occur in the liver. Thus, independent of a high or low 
metastatic propensity, the intrahepatic metastases are removed during liver 
transplantation, whereas following partial liver resection the remnant liver can 
harbor clinically undetectable metastases, which give rise to recurrences in 
due time. Our finding that patients with HCC with a low MVD have a worse 
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prognosis after partial liver resection might be explained by the well 
established phenomenon of a more aggressive behavior of hypoxic tumor cells 
(31, 32). Based on this, low MVD HCCs might have a higher fraction of hypoxic 
tumor cells resulting in a more aggressive tumor cell population, with a higher 
chance of intrahepatic metastases. 
In conclusion, we found a low endothelial cell proliferation rate, high SMA 
coverage of vessels, and no correlation between arterial blood supply and 
MVD both in cirrhotic and non-cirrhotic HCCs. It appeared that the endothelial 
cell compartment of HCC microvessels demonstrates a rather low turnover 
state. The highly comparable findings in cirrhotic and non-cirrhotic HCCs in 
this study are a strong argument to also evaluate sorafenib in patients with 
advanced non-cirrhotic HCCs. 
36
                                                                       Chapter 2
37
Reference 
(1) El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular 
carcinogenesis. Gastroenterology 2007;132:2557-76. 
(2) Ribes J, Cleries R, Esteban L, et al. The influence of alcohol consumption and 
hepatitis B and C infections on the risk of liver cancer in Europe. J Hepatol 
2008;49:233-42. 
(3) Medina J, Arroyo AG, Sanchez-Madrid F, et al. Angiogenesis in chronic inflammatory 
liver disease. Hepatology 2004;39:1185-95. 
(4) Lubrano J, Huet E, Tsilividis B, et al. Long-term outcome of liver resection for 
hepatocellular carcinoma in noncirrhotic nonfibrotic liver with no viral hepatitis or alcohol 
abuse. World J Surg 2008;32:104-9. 
(5) Pandharipande PV, Krinsky GA, Rusinek H, et al. Perfusion imaging of the liver: 
current challenges and future goals. Radiology 2005;234:661-73. 
(6) Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular 
carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association 
for the Study of the Liver. J Hepatol 2001;35:421-30. 
(7) Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 
2004;41:864-80. 
(8) Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6.  
(9) Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of 
vasculartargeted therapies. Clin Cancer Res 2005;11:416-20. 
(10) Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular 
carcinoma. N Engl J Med 2008;359:378-90. 
(11) Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral 
antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases 
involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. 
(12) de Jong KP, Vermeulen.P.B., Van Marck E, et al. Endothelial cell apoptosis in the 
context of quantification of angiogenesis in solid human adenocarcinomas: a novel double 
immunolabelling technique to identify endothelial cell apoptosis. Eur J Cancer 
2006;42:97-100. 
(13) Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the 
methodology and criteria of evaluation of angiogenesis quantification in solid human 
tumours. Eur J Cancer 2002;38:1564-79. 
(14) Bae KT, Heiken JP. Scan and contrast administration principles of MDCT. Eur Radiol 
2005;15 Suppl 5:E46-E59. 
(15) Zeng W, Gouw AS, van den Heuvel MC, et al. The angiogenic makeup of human 
hepatocellular carcinoma does not favor vascular endothelial growth 
factor/angiopoietin-driven sprouting neovascularization. Hepatology 2008;48:1517-27. 
(16) Dome B, Hendrix MJ, Paku S, et al. Alternative vascularization mechanisms in cancer: 
Pathology and therapeutic implications. Am J Pathol 2007;170:1-15. 
37
Chapter 2                                                                        
38
(17) Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat 
Rev Cancer 2008;8:579-91. 
(18) Leenders WP, Kusters B, Verrijp K, et al. Antiangiogenic therapy of cerebral 
melanoma metastases results in sustained tumor progression via vessel co-option. Clin 
Cancer Res 2004;10:6222-30. 
(19) Park YN, Yang CP, Fernandez GJ, et al. Neoangiogenesis and sinusoidal 
"capillarization" in dysplastic nodules of the liver. Am J Surg Pathol 1998;22:656-62. 
(20) Roncalli M, Roz E, Coggi G, et al. The vascular profile of regenerative and dysplastic 
nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 
1999;30:1174-8. 
(21) Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence 
after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 
2002;20:1775-85. 
(22) Mitsuhashi N, Shimizu H, Ohtsuka M, et al. Angiopoietins and Tie-2 expression in 
angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 
2003;37:1105-13. 
(23) Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence 
of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 
2004;130:497-513. 
(24) DeLeve LD, Wang X, Hu L, et al. Rat liver sinusoidal endothelial cell phenotype is 
maintained by paracrine and autocrine regulation. Am J Physiol Gastrointest Liver Physiol 
2004;287:G757-G763. 
(25) Nanashima A, Yano H, Yamaguchi H, et al. Immunohistochemical analysis of tumor 
biological factors in hepatocellular carcinoma: relationship to clinicopathological factors 
and prognosis after hepatic resection. J Gastroenterol 2004;39:148-54. 
(26) Esnaola NF, Mirza N, Lauwers GY, et al. Comparison of clinicopathologic 
characteristics and outcomes after resection in patients with hepatocellular carcinoma 
treated in the United States, France, and Japan. Ann Surg 2003;238:711-9. 
(27) Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological 
characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J 
Clin Pathol 2004;57:867-71. 
(28) Wang B, Gao ZQ, Yan X. Correlative study of angiogenesis and dynamic 
contrastenhanced magnetic resonance imaging features of hepatocellular carcinoma. 
Acta Radiol 2005;46:353-8. 
(29) El-Assal ON, Yamanoi A, Soda Y, et al. Clinical significance of microvessel density 
and vascular endothelial growth factor expression in hepatocellular carcinoma and 
surrounding liver: possible involvement of vascular endothelial growth factor in the 
angiogenesis of cirrhotic liver. Hepatology 1998;27:1554-62. 
(30) Kim CK, Lim JH, Park CK, et al. Neoangiogenesis and sinusoidal capillarization in 
hepatocellular carcinoma: correlation between dynamic CT and density of tumor 
microvessels. Radiology 2005;237:529-34. 
(31) Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. 
Cancer Metastasis Rev 2007;26:319-31. 
38
                                                                       Chapter 2
39
(32) Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, 
noninvasive measurement by imaging, and value of its measurement in the management 
of cancer therapy. Int J Radiat Biol 2006;82:699-757. 
(33) Tanigawa N, Lu C, Mitsui T, et al. Quantitation of sinusoid-like vessels in 
hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 
1997;26:1216-23. 
(34) Sun HC, Tang ZY, Li XM, et al. Microvessel density of hepatocellular carcinoma: its 
relationship with prognosis. J Cancer Res Clin Oncol 1999;125:419-26. 
(35) Ho JW, Poon RT, Sun CK, et al. Clinicopathological and prognostic implications of 
endoglin (CD105) expression in hepatocellular carcinoma and its adjacent nontumorous 
liver. World J Gastroenterol 2005;11:176-81. 
(36) Yang LY, Lu WQ, Huang GW, et al. Correlation between CD105 expression and 
postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 
2006;6:110. 
(37) Zhang Q, Chen X, Zhou J, et al. CD147, MMP-2, MMP-9 and MVD-CD34 are 
significant predictors of recurrence after liver transplantation in hepatocellular carcinoma 
patients. Cancer Biol Ther 2006;5:808-14. 
(38) Yao Y, Pan Y, Chen J, et al. Endoglin (CD105) expression in angiogenesis of primary 
hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 
and VEGF. Ann Clin Lab Sci 2007;37:39-48. 
39
Chapter 2                                                                        
40
40
                                                                                
41
CHAPTER 
The angiogenic makeup of human 




Wenjiao Zeng,1,5 Annette S.H. Gouw,1 Marius C. van den Heuvel,1 Peter J. 
Zwiers,2 Pieter E. Zondervan,4 Sibrand Poppema,1 Nong Zhang,5 Inge 
Platteel,1 Koert P. de Jong,3 and Grietje Molema2
1Department of Pathology, the 2Department of Pathology and Medical Biology, 
Medical Biology Section, and the 3Department of Surgery, Division of 
Hepatopancreatobiliary Surgery and Liver Transplantation, University Medical 
Center Groningen, University of Groningen, Groningen, the Netherlands. 
4Department of Pathology, Erasmus University Medical Center, Rotterdam, the 
Netherlands. 
5Department of Pathology, Shanghai Medical College, Fudan University, 
Shanghai, China. 
Hepatology 2008; 48:1517-1527 
41
Chapter 3                                                                        
42
Abstract 
Quantitative data on the expression of multiple factors that control 
angiogenesis in hepatocellular carcinoma (HCC) are limited. A better 
understanding of the mechanisms underlying angiogenesis in HCC will 
improve the rational choice of anti-angiogenic treatment. We quantified gene 
and protein expression of members of the Vascular Endothelial Growth Factor 
(VEGF) and Angiopoietin systems and studied localization of VEGF, its 
receptors VEGFR-1 and -2, Angiopoietin (Ang) -1 and -2, and their receptor 
Tie-2, in HCC in non-cirrhotic and cirrhotic livers. We employed real-time 
RT-PCR, Western blot, and immunohistology, and compared the outcome with 
highly angiogenic human renal cell carcinoma (RCC).   
HCC in non-cirrhotic and cirrhotic livers expressed VEGF and its receptors to a 
similar extent as normal liver, although in cirrhotic background VEGFR-2 levels 
in both tumor and adjacent tissue were decreased. Ang -1 expression was 
slightly increased compared to normal liver, while Tie-2 was strongly 
downregulated in the tumor vasculature. Ang -2 mRNA levels were also low in 
HCC of both non-cirrhotic and cirrhotic livers, implying that VEGF driven
angiogenic sprouting accompanied by Angiopoietin-driven vascular 
destabilization is not pronounced. In RCC, VEGF-A levels were one order of 
magnitude higher. At the same time, endothelially expressed Ang -2 was over 
30 fold increased compared to expression in normal kidney, while Ang -1 
expression was decreased.  
Conclusion: In hepatocellular carcinoma, tumor vascularization is not per se
VEGF / Angiopoietin driven. However, increased CD31 expression and 
morphological changes representative of sinusoidal capillarization in tumor 
vasculature indicate that vascular remodeling is taking place. This portends 
that therapeutic intervention of HCC at the level of the vasculature is optional, 
and that further studies into the molecular control thereof are warranted. 
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Hepatocellular carcinoma (HCC) is the fifth most common tumor 
worldwide, and the third cause of cancer-related death (1). The grave 
prognosis of HCC is a consequence of the absence of adequate curative 
options. Therapeutic possibilities are seriously incapacitated by the fact that 
the vast majority of HCC develops in patients with cirrhotic livers which is the 
end stage of a chronic liver disease (2). Liver transplantation, partial 
hepatectomy or local ablation are the only intentionally curative treatment 
options but are restricted to highly selected patient categories and the overall 
survival in general remains poor (3, 4).  In addition, chemotherapeutic 
possibilities are limited (5). Advances in tumor biology have however, in recent 
years led to the development of novel therapeutics, among others agents that 
affect tumor controlled angiogenesis, several of which are currently under 
clinical trials (6). Evidence suggests that in different tumor types differential 
angiogenic activity can be present and that angiogenic activity is also 
dependent on the site of growth in different host organs. As a consequence, 
responsiveness to anti-angiogenic therapy can be differentially controlled (7). 
Insight in the molecular angiogenic features of HCC is therefore pivotal for 
selection of the proper drug class and treatment regimen tailored for the 
disease.  
HCC is regarded as a hypervascular tumor, a property that is applied as 
radiological characteristic in diagnosing HCC (8). Furthermore, numerous 
studies reported high microvessel density counts and the expression of VEGF 
and other angiogenic factors (9, 10). It remains unclear however, whether 
these parameters reflect an active, pro-angiogenic phenotype of HCC.  In a 
previous study we found that the majority of microvessels in HCC consists of 
mature vessels as evidenced by pericyte coverage, with concurrent low rate of 
endothelial cell proliferation and apoptosis of the tumor microvessels (11). 
These findings brought us to hypothesize that active angiogenesis in HCC is 
less robust than formerly assumed. Since HCC is a malignant transformation 
in which proliferation of malignant hepatocytes takes place in a 
well-vascularized niche, abundant vascularization of HCC could result from 
cooption or remodeling of the preexisting hepatic sinusoidal network, rather 
than from neo-vessel formation. Knowledge regarding the true angiogenic 
status is of essential importance in choice of therapy. 
The current working model of angiogenic sprouting describes vascular 
endothelial growth factor (VEGF) induced VEGF-Receptor (VEGFR)2 
signaling concomitant with vessel destabilization via the Angiopoietin/Tie-2 
system. In this model, overexpression of Angiopoietin (Ang)-2 as the dynamic 
component of the Ang/Tie-2 system, competes with Ang-1 for Tie-2 binding, 
resulting in inhibition of Tie-2 phosphorylation. As a consequence, the 
endothelium becomes prone to VEGFR induced signaling (12). To determine 
the angiogenic status of human HCC in cirrhotic and non cirrhotic livers, we 
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investigated gene and protein expression levels of VEGF-A, VEGFR-1 (Flt-1), 
VEGFR-2 (KDR), Ang-1, Ang-2, and their receptor tyrosine kinase Tie-2 using 
quantitative RT-PCR and Western Blot analysis in tumors, adjacent liver and 
normal liver tissues. The cellular localization of the proteins was by 
immunohistochemistry assigned to designated cell types. We compared the 
outcome with expression of the same angiogenic factors in renal cell 
carcinoma (RCC), which represents one of the most angiogenic human tumors 
known to date (13). 
Patients, methods and materials 
Patients and tissue samples  
All procedures and use of (anonymized) tissue were performed according 
to recent national guidelines. Tissue samples of 55 HCCs obtained from 21 
non-cirrhotic and 34 cirrhotic livers were included.  Demographic data are 
detailed in table 1. HCC samples were taken at the periphery of a tumor nodule 
to avoid necrotic areas, and separate from adjacent non-tumorous tissue.  
The 34 cirrhotic samples were harvested from explanted livers after orthotopic 
liver transplantation. The 21 non-cirrhotic patients underwent a partial 
hepatectomy. Samples of histologically normal liver (n= 9), obtained from 
surplus donor liver, or partial liver resection for benign disorders, were used as 
controls. Both for immunohistochemistry to localize protein expression, and for 
real-time RT-PCR and Western Blot to quantify gene respectively protein 
expression, the same tissue blocks were used, except for CD31 and CD34 
immunohistochemistry, which was performed on paraffin sections. 
Samples of RCC (n=5) were included as reference for a tumor type that is 
considered as highly angiogenic. Similar to HCC livers, adjacent non-tumorous 
renal tissue and samples of normal renal tissue were included (n = 2). The 
latter were obtained from discarded donor kidneys. 
Quantitative RT-PCR for mRNA analysis  
Total RNA was isolated with the RNAeasy Mini Kit (Qiagen, Leusden, 
Netherlands) with subsequent DNA removal using the RNase-free DNase set 
(Qiagen), both according to the protocol of the manufacturer. RNA was 
analyzed qualitatively by gel electrophoresis and quantitatively by Nanodrop 
ND-100 spectrophotometry (NanoDrop Technologies, Rockland, DE, USA), 
and consistently found to be intact and protein free. Reverse transcription and 
real-time PCR were performed as described previously (14), using one 
microgram of total cellular RNA for the synthesis of first-strand cDNA and 10 ng
cDNA for each PCR reaction. Exons overlapping primers and minor groove 
binder probes for real-time RT-PCR were purchased as Assay-on-Demand 
from Applied Biosystems (Nieuwekerk a/d IJssel, The Netherlands): 
housekeeping gene GAPDH (assay ID Hs99999905_m1), VEGF 
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(Hs00173626_m1), VEGFR-1 (Hs00176573_m1), VEGFR-2 
(Hs00176676_m1), Tie2 (assay ID Hs00176096_ml), Ang-1 (assay ID 
Hs00181613_ml), Ang-2 (assay ID Hs00169867_ml).  All PCR reactions were 
performed in triplicates. Control samples of distilled water and isolated RNA 
not subjected to reverse transcription were consistently found to be negative. 
TaqMan quantitative RT-PCR was performed in an ABI PRISM 7900HT
Sequence Detector (Applied Biosystems). Gene expression was normalized to 
the expression of the housekeeping gene GAPDH, yielding the relative gene 
expression value.  
Quantification of angiogenic proteins by Western Blot 
Of each frozen tissue block, 20 samples of 5 m thick tissue slices were 
lysed in radioimmunoprecipitation assay buffer [50 mM Tris HCl, pH 7.4, 150 
mM NaCl, 1% nonidet P-40, 0.25% Na-deoxycholate, 1 mM 
ethylenediaminetetraacetic acid, 1 mM sodium fluoride, 1 mM sodium 
orthovanadate, 100 g/ml phenylmethylsulfonyl fluoride, 1 g/ml aprotinin 
(Sigma), and 1 g/ml leupeptin (Roche), and 1 g/ml pepstatin (Roche)]. Cell 
debris was removed by centrifugation at 10,000g for 15 minutes, and protein 
concentration was measured using pyrogallol red-molybdate solution. 20-40 
Hg of protein lysates were separated on sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose 
membranes (0.45m, Bio-Rad laboratories; Hercules, CA). The membranes 
were next probed with primary antibodies at the indicated dilutions (table 2) 
followed by incubation with horse radish peroxidase-labeled secondary 
antibodies and treated with an enhanced chemiluminescent substrate for 
detection (Amersham Life Science, London, UK). After detection of protein of 
interest, the membranes were stripped with stripping buffer [200mM glycine, 
1%SDS, PH 2.0], and stained for -actin as loading control. Protein bands 
(intensity x mm2) were quantified using image analysis software (Quantity One, 
Bio-Rad). The volume of each sample was divided by the volume of -actin, 
yielding the protein expression value presented in the figures. Some HCC and 
liver tissue adjacent to tumor samples were left out from the analysis as 
insufficient amounts of protein were isolated for follow up by Western Blot. 
Immunohistology to identify cellular location of protein expression 
All antibodies and concentrations used for immunohistology are 
summarized in Table 2. 
For VEGF-A, VEGFR-1, VEGFR-2, Ang-1, Ang-2, and Tie2, 5 m
sections of frozen tissues were mounted on slides, dried overnight at room 
temperature. After fixation in acetone for 10 min, slides were incubated with 
primary antibodies at 4oC overnight.  Then endogenous peroxidase was 
blocked with 0.08% H2O2 for 30 minutes, followed by incubation with 
horseradish peroxidase-conjugated secondary and tertiary antibodies.  
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Table 1. The Demographic Data of Patients with HCC Studied






Male / Female 13/8 27/7 NS 
Age 56.9±17.5 54.5±14.9 NS 
Main tumor diameter 0-5 cm vs. >5 cm 2/19 25/9 <0.01
Venous invasion  Yes vs. No 15/6 15/19 NS 
Edmondson grade I and II vs. III and IV 13/8 25/9 NS 
1-anti-trypsin 0 1  
neonatal hepatitis 0 1  
cryptogenic 0 3  
Glycogen storage disease 0 1  
HCV 0 9  
HBV/HCV 0 3  
HBV 0 7  
primary biliary cirrhosis 0 1  
tyrosinemia 0 1  
alcohol 0 4  
non alcoholic  
steato-hepatitis 
0 1  





hemochromatosis 0 1  









Rabbit anti-VEGF-A (A-20) 1/1000 1/100 Santa cruz sc-152 
Goat anti-Ang-1 (N-18) 1/2000 1/100 Santa cruz sc-6319
Goat anti-Ang-2 (F-18) 1/3000 1/50 Santa cruz sc-7017
Rabbit anti-Tie2 (C-20) 1/300 1/50 Santa cruz sc-324 
Rabbit anti-VEGFR-1  1/100 abcam ab2350
Rabbit anti-VEGFR-2  1/100 abcam ab2349
Mouse anti- ß-actin 1/3000  abcam ab8226
Mouse anti-CD34  Ready to use Immunotech 1185 
HRP-conjugated rabbit anti-mouse Ig 1/1000 1/100 Dako P0260 
HRP-conjugated goat anti-rabbit Ig 1/1000 1/100 Dako P0448 
HRP-conjugated rabbit anti-goat Ig 1/1000 1/100 Dako P0160 
*Diluted in 5% nonfat milk/0.1% TBST; Diluted in 1% BSA/PBS; Diluted in 1% 
BSA/PBS+1% human albumin. 
Abbreviations: HRP, horseradish peroxidase; Ig, immunoglobulins. 
3-amino-9-ethylcarbazole was used to develop the staining reaction and 
sections were counterstained with heamatoxylin, then sections were mounted 
with Kaiser’s glycerine-gelatine. CD34 and CD31 were stained on formalin 
fixed tissue using clone Qbend 10 (Immunotech Marseille, France) 
respectively JC/70A (DAKO, Glostrup, Denmark) in a method as described 
previously (15), with a 30 minutes protease pretreatment for CD31. 
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Fig. 1. VEGF and its receptors are not up-regulated in HCC. (A) Relative gene expression 
of VEGF-A, VEGFR-1, and VEGFR-2 in normal livers (n = 9), in HCC in noncirrhotic livers 
(n= 21) and their respective adjacent tissues (n = 11), and in HCC in cirrhotic livers (n= 34) 
and their respective adjacent liver tissues (n = 23), as determined by quantitative RT-PCR. 
(B) Upper graph: representative VEGF-A western blot of five different samples and their 
-actin loading controls (N, normal liver; T, tumor; Adj, corresponding adjacent 
nontumorous liver). Lower graph: relative VEGF-A protein levels in normal livers (n= 9), 
HCC in noncirrhotic livers and their adjacent livers (n = 11), HCC in cirrhotic livers and 
their adjacent livers (n = 22), as detected by western blot. Values are given as mean; error 
bars represent the standard deviations. *P< 0.05; **P< 0.01; gray bars, normal liver; black 
bars, tumor; white bars, adjacent to tumor.
Statistics 
Quantitative data were expressed as mean ± SD. For data that did not 
show a normal distribution, logarithmic transformation of the data was 
performed. Independent-samples t-test was used to compare the mean values 
between groups, and paired-samples t-test was used to compare the mean 
values between tumors and adjacent tissues. The 2-test was used to analyze 
the relationship between categorical variables. For all statistical analyses, the 
level of significance was set at 0.05. SPSS 15.0 statistical software for 
windows (SPSS Inc., Chicago, USA) was used for all analyses.  
Due to the small number of normal kidney samples available, a statistical 
analysis could not be performed on normal kidney and RCC data generated.  
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Fig. 2. Localization of VEGF and VEGFR expression in HCC. Immunostaining of VEGF-A, 
VEGFR-1, and VEGFR-2 in HCC, its adjacent nontumor liver tissue, and normal liver 
(original magnification 100). 
Results 
In HCC neither VEGF-A nor VEGFRs are upregulated 
Results of quantitation of mRNA and protein levels of the VEGF system as 
analyzed by RT-PCR and Western blot, respectively, are summarized in figure 
1.  In HCC of both cirrhotic and non-cirrhotic livers, VEGF-A and its receptors 
were present, and their levels of expression were only moderately different 
from those in normal livers (VEGFR-1 and -2 Western blot data not shown). 
When comparing within the cirrhotic group HCC in viral infected background 
with HCC in non-viral infected background, no differences in gene and protein 
expression levels could be detected (Supportung Fig. 1).   
Immunohistologically, VEGF-A positive staining in normal livers was seen 
in endothelial cells of portal veins, hepatic arteries, terminal hepatic venules, 
and sinusoidal endothelial cells, as well as in the wall of hepatic arteries and in 
bile duct and ductular epithelial cells, but not in hepatocytes. In HCC, VEGF-A 
located in endothelial cells within the tumor although the staining intensity was 
less pronounced compared to that in normal liver and non-tumorous 
parenchyma adjacent to the tumor (figure 2). Tumor cells were negative.  
In normal livers the expression pattern of VEGFR-1 was similar to that of 
VEGFR-2, both were mainly associated with Kupffer cells (figure 2). Only a 
weak expression was observed in endothelial cells including sinusoidal 
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Fig. 3. Tie-2 is down-regulated in HCC while Angiopoietin (Ang)-1 and Ang-2 are slightly 
induced compared with normal liver. (A) Relative gene expression of Ang-1, Ang-2, and 
Tie-2 in normal livers (n=9), HCC in noncirrhotic livers (n=21), and their adjacent tissues 
(n=11), and HCC in cirrhotic livers (n =34), and their adjacent liver tissues (n= 23), as 
determined by quantitative RT-PCR. (B and C) Western blot of Ang-1 and Tie-2, 
respectively (N, normal liver; T, tumor; Adj, corresponding adjacent nontumorous liver). 
Upper graphs: representative western blot of five different samples and their -actin 
loading controls; Lower graphs: Quantitation of western blot analysis of all samples. 
Number of samples included: normal livers n =9, HCC in noncirrhotic livers and their 
adjacent livers, n=11, HCC in cirrhotic livers and their adjacent livers n=22. Values are 
given as mean; error bars represent the standard deviations. *P <0.05; **P<0.01; gray 
bars, normal liver; black bars, tumor; white bars, adjacent to tumor.
endothelial cells as well as in vessel walls. In HCC, VEGFR-1 and VEGFR-2 
were only weakly expressed in some tumor endothelial cells whereas all other 
structures were negative. Non-tumorous liver tissue adjacent to HCC both in 
non-cirrhotic and cirrhotic livers showed a similar pattern as in normal liver. In 
cirrhotic cases stromal cells in fibrous septa expressed VEGFR-1 and 
VEGFR-2. 
Ang-1 and Ang-2 expression are modestly changed in HCC  
The Ang-1 mRNA expression level was slightly, statistically significantly 
higher in HCC of both non-cirrhotic and cirrhotic livers and adjacent liver tissue 
in cirrhotic liver as compared to control livers with normal histology, (figure 3A).  
Accordingly, Ang-1 protein levels were slightly higher in non-cirrhotic HCC 
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Fig. 4. Localization of Ang-1, Ang-2, and Tie-2 expression in highly vascularized HCC. 
Morphological appearance of the vasculature in HCC, its adjacent nontumor liver tissue, 
and normal liver, as detected by CD34 immunohistochemical staining of formalin-fixed 
tissues, and respective immunostaining of Ang-1, Ang-2, and Tie-2 in HCC in frozen 
materials (original magnification 400_). Although Ang-2 is expressed in a sinusoidal 
distribution pattern in normal liver and normal liver adjacent to the tumor, its expression in 
HCC is scattered (picture) and mostly absent from tumor-associated vasculature.
Fig. 5. Angiopoietin-2 is absent
in HCC, while being abundantly
expressed in RCC. Top: Western
blot analysis of Ang-2 and
-actin of HCC from cirrhosis
and noncirrhosis background,
and RCC (N, normal liver; T,
tumor; Adj, corresponding
adjacent nontumorous tissue).
Lower: Representative pattern of
immunostaining of Ang-2 in RCC
(original magnification 200).
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(figure 3B). There was no significant difference between HCCs and adjacent 
liver tissues neither at mRNA nor at the protein level (figure 3A, 3B). While 
Ang-2 mRNA expression levels in HCC of cirrhotic livers were not significantly 
altered as compared to the adjacent liver and normal liver tissues, a 
statistically significant, yet small increase in mRNA of Ang-2 was observed in 
HCC of non-cirrhotic livers compared to adjacent and normal control liver 
(figure 3A). Also, Ang-2 mRNA level was higher in HCC in non-cirrhotic liver as 
compared to HCC in cirrhotic liver. In all liver and HCC samples, Ang-2 protein 
was below Western Blot detection limit (figure 5). Comparison of virus infected 
versus non-virus infected HCC in cirrhotic background revealed a 3 fold lower 
mRNA expression level of Ang-1 in virus infected HCC, while Ang-2 mRNA did 
not differ between groups. The lower Ang-1 mRNA level was not paralleled by 
lower protein expression (Supporting Fig. 1). 
Immunohistologically, Ang-1 positive cytoplasmic staining was seen in 
HCC cells and hepatocytes in adjacent and normal livers, with weak staining in 
vascular endothelium. Ang-2 staining was hardly detectable in HCC: only 
occasionally scattered Ang-2 expressing tumor associated endothelial cells 
were observed (Ffig. 4). In contrast, in adjacent and normal livers Ang-2 
positive sinusoidal endothelial cells (SEC) presented in a zonal distribution 
around terminal hepatic venules, while vascular endothelium was weakly 
expressing Ang-2.  
In addition, the expression of the Angiopoietin receptor Tie-2 was 
significantly lower in HCC compared to its expression in normal adjacent liver 
and normal liver, evidenced by both quantitative RT-PCR and Western Blot 
analysis (Fig. 3A/C). This difference was also visible by immunohistology 
(figure 4), with a sinusoidal pattern of Tie-2 expression in normal liver and 
tissue adjacent to the tumor, and a more scattered pattern in HCC.  
Differences in Tie-2 mRNA expression between virus infected and non-virus 
infected HCC were visible, yet small, and could not be substantiated with 
Western Blot analysis.
Expression levels of members of the VEGF and Angiopoetin/Tie-2 
system in RCC 
RCC is considered to be a tumor type with prominent angiogenic sprouting 
activity as a means to support tumor cell demands for nutrients and oxygen. 
We analyzed RCC in a similar way as we analysed HCC, to enable a direct 
comparison with the molecular features of HCC. A pattern of significant 
upregulation of components of the VEGF system was observed in RCC in 
comparison with normal kidney (Fig. 6). Besides a 4.5 fold increase in VEGF-A 
mRNA in RCC compared to normal kidney, VEGFR-1 expression was also 
increased. VEGFR-2 mRNA expression levels were at a similar level in RCC 
and in normal kidney.
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Fig. 6. Gene expression levels of the members of the VEGF and Tie-2 system in RCC. 
Relative gene expression of VEGF-A, VEGFR-1, VEGFR-2, Ang-1, Ang-2, and Tie-2 in 
normal kidney (n =2), RCC (n=5), and their adjacent tissues (n=2), as determined by 
quantitative RT-PCR. Data are presented as mean values and their respective standard 
deviations. Gray bars, normal kidney; black bars, RCC; white bars, adjacent to tumor. 
Fig. 7. HCC tumor vasculature gains CD31 expression. Immunostaining of CD31 in 
normal adjacent liver (A) and in HCC (B), demonstrating a phenotypical as well as 
morphological difference between normal sinusoidal endothelial cells and tumor 
endothelial cells (original magnification 100). 
In addition to these changes in the VEGF system, the Angiopoietins 
showed a remarkable shift in balance in RCC compared to normal kidney (Fig. 
6). While Ang-1 mRNA levels in the tumor were ~25% less compared to their 
levels in normal kidney tissue, Ang-2 mRNA was increased over 30 fold in the 
tumor. A similar shift in Angiopoietin balance was recently reported in RCC by 
(16). Although mRNA levels of different genes cannot be directly compared, 
the change in Ang-1/-2 mRNA ratio implies a shift toward a vessel 
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destabilization phenotype. The increased mRNA levels of Ang-2 in RCC were 
corroborated by Western Blot analysis, showing significant amounts of Ang-2 
protein in this tumor type.  Also by immunostaining, RCC presented as a 
tumor rich in Ang-2 positive vessels (Fig. 5), in contrast to HCC.  
HCC associated endothelium gains CD31 and CD34 expression 
In a liver with normal histology, the sinusoidal endothelial cells express the 
endothelial marker gene CD31 and CD34 to a limited extent, in the periportal 
areas (Fig. 4, 7A.), corroborating previously published data (17). Interestingly 
though, while the mean vascular density between the healthy sinusoidal 
network and the tumor vasculature did not dramatically change, tumor 
endothelium gained CD31 and CD34 expression (Fig. 4, 7B), indicative of a 
phenotypic change in endothelial cell behaviour taking place under the 
influence of tumor related (growth) factors.
Discussion  
The current study investigated the status of angiogenic sprouting in 
primary human hepatocellular carcinoma as represented by Ang/Tie-2 based 
vascular destabilization and VEGF driven angiogenic activation. We 
quantitatively and qualitatively compared the results with human RCC, which is 
a highly angiogenic tumor due to a mutation in one allele of the Von Hippel 
Lindau tumor suppressor gene, as a consequence of which several genes 
involved in angiogenic sprouting are overexpressed (13). We demonstrated 
that in HCC no major differences in VEGF/VEGFR and Ang/Tie-2 gene and 
protein expression exist compared to normal liver. In contrast, in RCC a 
strongly increased expression of Ang-2 was paralleled by a decrease in Ang-1 
and a significant increase in VEGF-A and VEGFR-1. These data imply that in 
HCC, irrespective whether they originate in a non-cirrhotic or cirrhotic liver, and 
irrespective whether they are from a viral or non-viral background, the tumor 
blood supply is regulated in a VEGF - Ang/Tie-2 independent manner. This 
observation has important implications for therapeutic decision making for 
anti-angiogenesis based therapy of HCC.   
Several studies reported on the expression of members of the VEGF 
system in HCC (18, 19), and also the members of the Angiopoietin family  
have been (semi-) quantitatively analyzed and related to VEGF and 
microvascular density (20, 21). Our data corroborated previous observations 
that no significant differences in VEGF-A expression exist between HCC and 
adjacent liver (22), and that Ang-1 was increased in HCC compared to normal 
liver (23). However, also some discrepancies became apparent. For example, 
in the study by Zhang et al.  all four angiogenes analyzed, i.c., Ang-1, Ang-2, 
Tie-2  and VEGF, were expressed at a similar level (21). In contrast, we found 
that VEGF expression in HCC  was one order of magnitude higher than that 
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of the Angiopoietins and Tie-2. The lower Tie-2 mRNA expression in HCC was 
substantiated by Western Blot (protein) and illustrated by 
immunohistochemistry. Although it is difficult to quantitatively compare 
quantitative RT-PCR based mRNA and Western Blot based protein levels, all 
data provided in our study point to a lower expression of Tie-2 in HCC than in 
normal liver. Amaoka and colleagues recently reported a relation between 
VEGF protein expression in HCC as determined by ELISA, and 
clinicopathological features. One important difference in analysis between their 
study and ours is the site from which the HCC samples were obtained. 
Amaoka retrieved tumor samples from non-necrotic HCC central areas, 
whereas we retrieved our samples from the periphery of the tumor nodules. 
Possibly, in more central tumor areas hypoxia is more prominent, resulting in 
higher VEGF levels and hence Tumor/Normal VEGF ratios exceeding 1, which 
was the case in 18/28 cases (24). 
The relation between VEGF/Angiopoietin expression and the angiogenic 
phenotype of HCC has been extensively addressed in recent years, yet the 
data remain difficult to interpret. In mouse models it was convincingly shown 
that development of HCC intraperitoneally or in the subcutaneous, a-vascular, 
pocket was dependent on the VEGF/Angiopoietin system(25, 26).That these 
factors are present in HCC in humans has been extensively reported ((18, 20, 
27) and others), yet their mere presence does not shed light on the question 
whether they represent active angiogenesis in the microenvironment of the 
tumor in the human liver. By relating our data on HCC to the expression levels 
of the same genes in human RCC, which is an established model for active 
angiogenesis in man, we placed the expression levels in HCC in broader 
perspective. One important finding in this respect was that in HCC the 
expression level of VEGF was only 20% of the level observed in RCC. 
Moreover, we identified a striking difference in Ang-1/-2 mRNA ratios between 
the two tumor types. While this ratio dramatically dropped from ~ 2 in normal 
kidney to 0.06 in RCC as a result of overexpression of Ang-2 concomitant with 
a decreased expression of Ang-1, in HCC it was ~ 0.3 in non-cirrhotic and 
cirrhotic HCC, which is in the same order of magnitude as reported previously 
in a small number of HCC in a cirrhotic background (23). In virus associated 
HCC the ratio was clearly lower (~ 0.1) than that in non-virus associated HCC 
(~ 1), which is attributed to both a reduced expression of Ang-1 and a slightly 
induced expression of Ang-2. Whether the virus associated HCC related 
dysbalance in Ang-1/-2 expression in the absence of induced VEGF-A 
production can give rise to tumor growth associated angiogenic sprouting (12) 
is unclear and should be subject of future study, e.g. by analysis of 
phospho-VEGFR-2 or phospho-Tie-2 / CD34 immunofluorescence double 
staining. 
The liver sinusoids may represent a specialized vascular bed that 
preferentially facilitates pathology related demands by vascular remodeling via 
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other mechanisms than angiogenic sprouting. Recently, Straub and colleagues 
showed that prolonged exposure of mice to Arsenic (III)  initiated vascular 
remodeling by SEC capillarization, which was paralleled by increased 
sinusoidal CD31 expression, similar to our observation in HCC (28). In this 
respect, our previous observation of increased numbers of alpha-smooth 
muscle actin positive cells adjacent to CD34 expressing sinusoidal cells in 
HCC (11), along with our current finding of increased Ang-1 in HCC support 
the concept of sinusoidal remodeling in which recruitment of pericytes is 
stimulated by Ang-1 (29). Additionally, some tumors acquire their vasculature 
by vessel cooption instead of angiogenic sprouting (30, 31). At present, we 
lack a vascular marker for  (sinusoidal) endothelial cooption, and hence 
cannot test the hypothesis that HCC is also nourished by cooption more than 
by angiogenic sprouting. Yet, the finding that HCC can grow in the absence of 
increased expression of VEGF and a destabilized Ang/Tie-2 phenotype puts 
forward an intriguing premise that the permissive role of SEC may be a general 
feature for tumor growth in the liver. The recent observations that the 
expression of VEGF-A in primary colorectal carcinoma is higher than in 
colorectal carcinoma metastases in the liver (32) and that primary pancreatic 
cancer expresses twice as much VEGF as compared to its metastasis in the 
liver (33) are compelling indications that the liver niche indeed represents a 
microenvironment that can actively influence tumor growth associated 
processes.  
In light of the current findings, the recently reported clinical effects of 
sorafenib and sunitinib in patients with HCC seem contradictory (34-36). They 
can however be explained by the fact that sorafenib and sunitinib are 
multikinase inhibitors that do not only affect VEGFR mediated signal 
transduction but also PDGF receptor, B- and C-RAF, cKit, and flt3 activity. Raf 
mediated enhanced extracellular signal-regulated-kinase (ERK)/Mitogen 
activated-protein kinase signalling is implicated in proliferative and migratory 
capacity of HCC tumor cells (37). Inhibition of the phosphorylation of MEK and 
ERK, in combination with MEK/ERK independent molecular changes, resulted 
in tumor cell proliferation inhibition and apoptosis induction. In vivo in the 
PLC/PRF/5 xenograft model, the sorafenib associated tumor cell apoptosis 
induction coincided with a reduced microvessel density, but direct tumor 
vascular effects were not reported (38). It is not unlikely, therefore, that these 
multikinase inhibitors primarily affect tumor cells and their production of 
angiogenic factors, leading to indirect anti-angiogenic effects. 
Knowledge on the exact status of the molecular processes underlying 
vascular remodeling  supporting tumor outgrowth is essential for therapeutic 
intervention. From our data, HCC growth in both non-cirrhotic and cirrhotic liver 
is not predominantly VEGF/Angiopoietin driven. Still, the tumor microvascular 
capillaries are distinctly different from SEC, both morphologically and 
phenotypically. The trabeculae and pseudoglands of HCC are covered by 
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endothelial cells which phenotypically differ from SEC as visualized in our 
study by the expression of CD31, as well as CD34 , antigens that are 
expressed to a limited extent or even absent on normal SEC. Apart from the 
sinusoidal like vasculature, HCC also contains so called unpaired arteries 
which are haphazardly distributed small arteries without accompanying bile 
duct. Possibly, epidermal growth factor family members including Betacellulin 
and EGF-receptor (39, 40) or other (angiogenic) factors and their respective 
receptors such as platelet derived growth factor (PDGF)/PDGFR can 
influence tumor vascularization processes (41, 42). Of interest in this respect is 
furthermore the recent publication by Lai and colleagues, in which they 
showed that the enzyme sulfatase-2 positively affected the binding and 
subsequent downstream signal transduction of FGF-2 (43). As sulfatase-2 was 
overexpressed in approximately 60% of HCC studied, it is tempting to 
speculate that HCC associated vascular remodeling can be driven by FGF-2 
without FGF-2 being overexpressed. Further detailing on the exact molecular 
control of HCC driven vascularization is needed to provide a rationale for 
vasculature directed therapy (44) with or without combination with tumor 
directed therapeutics. 
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Abstract 
Tumor growth requires vascular support which can be provided by 
angiogenesis.  Vascular endothelial growth factor (VEGF), its receptors and 
the Angiopoietin (Ang)/Tie-2 system are involved in the molecular control of 
angiogenic sprouting. In a previous study we observed a relatively low 
VEGF/Ang-Tie-2 dependent angiogenic activity in hepatocellular carcinoma. In 
the current study we investigated the vascular changes and angiogenic status 
of 21 benign hepatic tumors consisting of hepatic adenoma (HCA) and focal 
nodular hyperplasia (FNH). We studied gene expression and protein 
expression profiles of VEGF-A, its receptors VEGFR-1 and -2 as well as Ang-1, 
Ang-2, and their receptor Tie-2, in comparison with histologically normal liver 
samples. The cellular localization of the proteins was investigated by 
immunohistology. 
We observed no changes in expression of VEGF-A, nor its receptors in 
HCA and FNH. Ang-1 was upregulated in FNH and HCA concurrent with 
increased Tie-2 in FNH. In both tumor types Ang-2 levels were similar to those 
in normal liver samples. Immunohistologically, hepatocytes of both tumor types 
showed abundance of Ang-1 protein expression whereas Tie-2 was expressed 
by sinusoidal endothelium. CD34 and SMA staining showed increased 
expression, in a sinusoidal pattern in HCA whereas in FNH this increase was 
present in the vicinity of the central scar and scar-like structures.  
Conclusion: The unaltered VEGF-A and Ang-2 status in FNH and HCA 
implied that VEGF-A/Ang-Tie2 dependent angiogenesis is not occurring in 
these tumors. The increased Ang-1 and Tie-2 expression, the presence of 
sinusoidal capillarization, activated myofibroblasts, and vascular features, 
which are compatible with Ang-1/Tie-2 effects, suggest a role for Ang-1/Tie-2 
induced vascular remodeling of the hepatic microvasculature in FNH and HCA. 
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Introduction 
Tumor angiogenesis refers to the process of neovessel formation to 
provide a tumor with the necessary vascularization to grow and to metastasize 
in case of malignant growth. Studies on tumor angiogenesis predominantly 
deal with malignant tumors although benign neoplastic counterparts can be 
found in every organ. Some of these benign variants might represent 
premalignant disease, e.g. colorectal adenomatous polyps. Benign 
proliferative lesions would also require new vessel formation to grow; yet, 
studies on angiogenesis in these tumors are scarce. 
In a previous study we investigated the angiogenic characteristics of 
human hepatocellular carcinoma (HCC), both in cirrhotic and non-cirrhotic 
livers. Focusing on the Angiopoietin/Tie-2 system and VEGF-A and its 
receptors, we observed that human HCC is devoid of any significant Ang-2 
upregulation concurrent with an increase of VEGF-A expression as a prelude 
to VEGF-R signaling to vascular sprouting. This finding contrasted with their 
pattern in the highly angiogenic human renal cell carcinoma, which is known to 
engage in active angiogenesis via the Ang-2/Tie-2 - VEGF/VEGFR axis (1). 
Based on this observation we hypothesized that the absence of 
VEGF-A/Ang-Tie-2 driven sprouting angiogenesis in HCC is due to the fact 
that this malignant growth of hepatocytes is situated in a natural habitat which 
is a well vascularized soil provided by the hepatic sinusoidal network. It is 
conceivable that vascular remodeling in this rich and possibly permissive 
vascular soil may be fully capable of providing the required supplementary 
blood supply for both malignant and benign tumor growth without the additional 
need for robust neovessel formation.  
To further investigate this hypothesis, we studied gene and protein 
expression levels of VEGF-A, VEGFR-1 and 2, Ang-1, Ang-2 and their 
receptor Tie-2 in hepatocellular adenoma (HCA) and focal nodular hyperplasia 
(FNH). The cellular localization of these proteins was analyzed by 
immunohistology and we compared the outcome with the pattern in 
histologically normal liver samples. Additionally, we also studied CD34 and 
SMA expression in these tumors. 
Patients and methods 
Patients and tissue samples 
Frozen tissue samples of 9 FNH (mean age 33.1±4.7), and 12 HCA (mean 
age 37.5±10.5) patients who underwent partial liver resection for the tumor 
were included. All patients were females. One patient in the HCA group had 2 
separate tumors, so the total of tumor samples was 9 FNH and 13 HCA. We 
also included 9 samples of livers showing normal histological features. These 
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samples were collected from surplus material of donor liver, hemangioma liver 
and a traumatic liver rupture. Adjacent, non tumorous liver tissue was also 
included in the study. The tumors were histologically classified according to 
the Bordeaux update of the classification of benign hepatic nodules (2) and 
their phenotype was further confirmed by immunohistology using the profiles 
recommended by Bioulac-Sage et al (3). All lesions represented benign 
hepatocellular proliferative lesions in an otherwise non-diseased liver.  
Quantitative RT-PCR for mRNA analysis 
Total RNA was isolated with the RNAeasy Mini Kit (Qiagen, Leusden, 
Netherlands) with subsequent DNA removal using the RNase-free DNase set 
(Qiagen), both according to the protocol of the manufacturer. RNA was 
analyzed qualitatively by gel electrophoresis and quantitatively with Nanodrop 
ND-100 spectrophotometer (NanoDrop Technologies, Rockland, DE, USA). 
Reverse transcription and real-time PCR were performed as described 
previously (4). Briefly, one microgram of total cellular RNA was used for the 
synthesis of first-strand cDNA and 10 ng cDNA was used for each PCR 
reaction. Exons overlapping primers and minor groove binder (MGB) probes 
used for real-time RT-PCR were purchased as Assay-on-Demand from 
Applied Biosystems (Nieuwekerk a/d IJssel, The Netherlands): housekeeping 
gene GAPDH (assay ID Hs99999905_m1), VEGF (Hs00173626_m1), 
VEGFR-1 (Hs00176573_m1), VEGFR-2 (Hs00176676_m1), Tie2 (assay ID 
Hs00176096_ml), Angpt-1 (assay ID Hs00181613_ml), Angpt-2 (assay ID 
Hs00169867_ml).  TaqMan quantitative RT-PCR was performed in an ABI 
PRISM 7900HT Sequence Detector (Applied Biosystems). Amplification was 
performed with the following cycling conditions: 2 min at 50°C, 10 min at 95°C, 
and 40 two-step cycles of 15 s at 95°C and 60 s at 60°C. Triplicate real-time 
PCR analyses were executed for each sample, and the obtained threshold 
cycle values (Ct) were averaged. Gene expression was normalized to the 
expression of the housekeeping gene GAPDH, yielding the relative gene 
expression value. Control samples of distilled water and randomly chosen 
RNA isolates that were not subjected to reverse transcriptase were 
consistently found to be negative. 
Western blot analysis 
Of each frozen tissue block, 20 samples of 5 m thick tissue slices were lysed 
in radioimmunoprecipitation assay (RIPA) buffer [50 mM Tris HCl, pH 7.4, 150 
mM NaCl, 1% nonidet P-40, 0.25% Na-deoxycholate, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 1 mM sodium fluoride, 1 mM sodium 
orthovanadate, 100 g/ml phenylmethylsulfonyl fluoride (PMSF), 1 g/ml 
aprotinin (Sigma), and 1g/ml leupeptin (Roche), and 1g/ml pepstatin 
(Roche)]. Cell debris was removed by centrifugation at 10,000g for 15 minutes, 
and protein concentration was measured using pyrogallol red-molybdate 
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Table 1. Antibodies used in Immunohistology (IH)
Antibody        Dilution Pretreatment  Source/Code 
Rabbit anti-VEGF-A (A-20    1/100†            Santa cruz/sc-152 
Goat anti-Ang-1 (N-18)      1/100†            Santa cruz/ sc-6319 
Goat anti-Ang-2 (F-18)        1/50†            Santa cruz /sc-7017 
Rabbit anti-Tie2 (C-20)        1/50†            Santa cruz/ sc-324 
Rabbit anti-VEGFR-1     1/100†            Abcam/ ab2350 
Rabbit anti-VEGFR-2     1/100†            Abcam/ ab2349 
Mouse anti-CD34          Ready to use        Immunotech /QBend10 
Mouse anti-SMA                    Immunotech/1A4 
Mouse anti-human amyloid A   1/50 Microwave    Dako/mc-1 
Rabbit polyclonal to LFABP   1/50    Microwave    Abcam/ab7807 
Mouse anti-glutamine synthetase  1/400 Microwave    Biosciences/mab302 
HRP-conjugated rabbit anti-mouse Ig  1/100‡            Dako P0260 
HRP-conjugated goat anti-rabbit Ig   1/100‡        Dako P0448 
HRP-conjugated rabbit anti-goat Ig   1/100‡        Dako P0160 
† diluted in 1% BSA/PBS; ‡ diluted in 1% BSA/PBS + 1% human albumin; HRP: horse 
radish peroxidase
solution. Indicated amounts of lysates were separated on sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to 
nitrocellulose membranes (0.45m, Bio-Rad laboratories; Hercules, CA). The 
membranes were next probed with various primary antibodies (VEGF-A 
1:1000, Santa Cruz sc-152, Angpt-1 1:1000 Santa Cruz sc-6319, Angpt-2 
1:2000 Santa Cruz sc-7017, Tie2 1:300 Santa Cruz sc-324), diluted in 5% 
no-fat milk /0.1% TBST) at 4oC overnight, followed by incubation with 
peroxidase-labeled secondary antibodies (1:1000) and treated with an 
enhanced chemiluminescent substrate for detection of HRP (Amersham Life 
Science, London, UK). Then the membranes were stripped with 25mM 
glycine/1% SDS (PH 2.0) buffer, and ß-actin (mouse anti- ß-actin, 1:3000, 
Abcam, ab8226) was detected as loading control. Protein expression observed 
as electrophoretic bands in X-ray films was quantified using image analysis 
software (Quantity One, Bio-Rad) to calculate the volume of bands (intensity x 
mm2). For each protein, the volume of each sample was divided by the volume 
of control (-actin), yielding the relative protein expression value. 
Immunohistology 
The antibodies used for immunohistology, their dilutions and sources are 
listed in table 1. Staining for VEGF-A, VEGF-R1 and R2, Angiopoietin-1 and 2 
and Tie-2 were all performed on frozen sections. 5 m frozen sections, dried 
overnight, were fixed in acetone and incubated with primary antibodies at 4oC
overnight.  Endogenous peroxidase was blocked with 0.08% H2O2 for 30 
minutes, followed by incubation with horseradish peroxidase-conjugated 
secondary and tertiary antibodies (1:100). AEC was applied for the staining 
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reaction and haematoxyline for nuclear counterstaining.  
The three markers for immunophenotyping HCA and FNH, glutamine 
synthetase (GS), serum amyloid A protein (SAA) and liver fatty acid binding 
protein-1 (LFABP-1) were applied on paraffin sections as were the staining 
with anti CD34 and anti SMA. In short, 47m sections were deparaffinized, and 
microwave pretreatment was applied except for CD34 and SMA. After 
blocking endogenous peroxidase by H2O2, slides were incubated with the 
primary antibody followed by the secondary antibody. Diaminobenzidin was 
applied to visualize the staining reaction and hematoxylin for counterstaining.  
Results 
The benign hepatic tumors included in this study were classified according 
to the guidelines of the Bordeaux update and immunohistologic profiles as 
recommended by Bioulac-Sage et al. (2,3). All 9 samples of FNH showed the 
typical fern-like pattern of GS expression whereas SAA and LFABP-1 
expression was similar to the pattern observed in the adjacent non-tumorous 
liver. The HCA group consisted of six tumors showing the immunophenotype 
of inflammatory type adenoma with diffuse increase of SAA expression, two 
samples demonstrating lack of LFABP-1, one with diffuse increase of GS and 
four tumors without any specific immunophenotypic characteristics.
Because angiogenic sprouting is considered to mainly originate from the 
microvasculature we investigated the phenotypical changes of the 
microvasculature, using CD34 as a vascular endothelial marker and SMA as 
the marker of pericytes and activated hepatic stellate cells or myofibroblasts. 
In histologically normal livers CD34 is only expressed by vascular 
endothelial cells (VEC) and a small rim of periportal hepatic sinusoidal 
endothelial cells (HSEC) (fig 1). In FNH increased CD34 sinusoidal expression 
is found, mainly around the central scar and scar like structures within the 
tumor parenchyma (fig 1) in a decreasing gradient pattern from the scar 
deeper into the parenchyma. In HCA the HSEC showed increase of CD34  
expression (fig 1) in a variable, non-specific pattern, either patchy or diffuse. 
The expression of SMA in histologically normal livers is limited to vascular 
walls (fig 1). In FNH an obvious increase is seen in the stromal tissue of the 
central scar and scar like structures as well as the sinusoids surrounding these 
structures. The pattern is similar to the gradient described for CD34 expression. 
In HCA variable increase of sinusoidal SMA expression is noted (fig 1), 
ranging from scant in the sinusoids to a diffuse increase. The SMA staining 
also emphasized the presence of haphazardly distributed single arteries. 
No specific patterns were observed in CD34 and SMA expression 
between the different subtypes of HCA.
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Table 2. Cellular distribution of the angiogenic factors by immunohistology 
 Hepatocytes HSEC VEC Bile duct Bile ductules 
Protein N FNH HCA N FNH HCA N FNH HCA N FNH HCA N FNH HCA 
VEGF-A    + + ± + + + + A A + ± A*
VEGFR-1    ± ± ± ± ± ± + A A + + A*
VEGFR-2    ± + ± ± ± ± + A A + + A*
Ang-1 + + +       ± A A ± ± A*
Ang-2    + ± ± ± ± ± + A A + ± A*
Tie-2    + + + + ± ±  A A  ± A*
A = absent; A* = absent, but sometimes present in inflammatory type HCA; N = normal 
liver samples; FNH = focal nodular hyperplasia; HCA = hepatocellular adenoma; HSEC = 
hepatic sinusoidal endothelial cells; VEC = vascular endothelial cells.
Figure 1: Expression of SMA and CD34 by immunohistology. 
VEGF-A and receptors: no up-regulation in FNH and HCA. 
In figure 2 results of the quantitative expression analyses of the VEGF 
system are summarized. FNH and HCA showed no significant alterations of 
VEGF-A expression both at the gene expression and protein levels when 
compared with normal liver samples. A subdivision of the HCA group into the 
largest subgroup of inflammatory type HCA did not reveal any significant 
differences in both gene expression and protein levels (not shown). A similar 
pattern was observed for VEGF-R2 expression. VEGF-R1 gene expression in 
FNH was lower than in normal liver samples (figure 2). 
The cellular localization of VEGF-A and both receptors was studied by 
immunohistology (figure 3 and table 2). VEGF-A showed a similar cellular 
localization in normal liver samples, FNH and HCA. VEGF-A was expressed 
by HSEC and VEC while hepatocytes were negative, Bile ducts and bile 
ductules were positive in normal livers. Weaker expression was seen in 
ductular  
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Figure 2: a, Relative gene expression of VEGF-A, VEGFR-1 and VEGFR-2 in normal 
livers (n = 9), FNH (n = 9) and their respective adjacent tissues (n = 5), and Adenoma (n= 
13) and adjacent liver tissue (n=4), as determined by quantitative RT-PCR. Relative gene 
expressions represent values adjusted to GAPDH. b, top: Western blot of VEGF-A 
(N=normal liver, T=tumor, Adj=corresponding adjacent nontumorous liver); The HCA  
was divided into I-HCA ( inflammatory type adenoma) and the rest-group. low: relative 
VEGF-A protein in normal livers (n = 9), FNH (n = 9) and their respective adjacent tissues 
(n = 5) , HCA (n=13) and adjacent liver tissue (n=4), as detected by Western blot. Values 
are given as mean; error bars represent the standard error of the mean. *P <.05; **P <.01. 
Gray bars: normal liver; black bars: tumor; white bars: adjacent to tumor. 
structures of FNH and when ductules were present, also in the inflammatory 
subtype of HCA. VEGF-A expression in HSEC of HCA was much less intense 
than in FNH and normal livers. In the sinusoidal spaces of HCA VEGF-A was 
predominantly seen in macrophages. VEGF-A was also readily visible in the 
stromal cells in the central scar of FNH. VEGF-R1 and VEGF-R2 showed a 
similar localization in FNH, HCA and normal livers.   Both receptors were 
absent in hepatocytes. The most obvious expression of both receptors was 
present in sinusoidal macrophages whereas HSEC and VEC showed a weaker 
expression.  Stromal cells, macrophages and the biliary ductules in the 
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Figure 3: Localization of VEGF-A and VEGFR- and R2 expression by immunohistology. 
Frozen 56m sections of tissue were immunohistologically stained as described in 
Materials and Methods. In HCA, FNH and normal livers VEGF-A & Receptors are 
expressed on hepatic sinusoidal endothelial cells whereas in FNH there is also expression 
in stromal cells in the central scar and on ductular structures.
Ang-1 and Tie-2 expression is increased in FNH and HCA 
FNH and HCA showed up-regulation of Ang-1 as compared with normal 
liver samples at the gene expression level, although the extent of increase was 
small and not visible at the protein level (figure 4).  In FNH but not in HCA this 
pattern was also observed for Tie-2. No significant differences in gene 
expression were seen for Ang-2 between the tumors and normal liver samples, 
except for the up-regulation of Ang-2 in the adjacent liver tissue of FNH. No 
differences could be substantiated for Ang-1 and Tie-2 at the protein level. 
Ang-2 was below detection limit in Western Blot analysis. Previously, we were 
able to demonstrate Ang-2 protein expression in renal cell carcinoma extract 
(1), indicating that the experimental protocol used per se is appropriate for the 
detection of this protein.  
In figure 5 the cellular localization of Ang-1, Ang-2 and Tie-2 is depicted. 
In both tumor types and normal liver samples cytoplasmic staining of Ang-1 
was readily observed in hepatocytes. Less obvious expression was observed 
in bile ducts and ductules. Ang-1 was absent in HSEC and VEC. 
Ang-2 was present by HSEC while VEC showed a less pronounced 
expression.  Hepatocytes were negative. Ang-2 was also present in bile ducts  
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Figure 4: a, Relative gene expression of Ang-1, Ang-2 and Tie-2 in normal livers (n = 9), 
FNH (n = 9) and their respective adjacent tissues (n = 5), and Adenoma (n= 13) and 
adjacent liver tissue (n=4), as determined by quantitative RT-PCR. Gene expression 
values represent relative values adjusted to GAPDH. b. Western blot of Ang-1 and Tie-2 
(N=normal liver. T=tumor. Adj=corresponding adjacent nontumorous liver). The HCA was 
divided into I-HCA (inflammatory type adenoma) and the non-inflammatory HCA 
rest-group. c, Relative protein levels of Ang-1 and Tie-2 in normal livers (n = 9), FNH (n = 
9) and their adjacent tissues (n = 5), and HCA (n= 13) and adjacent liver tissue (n=4), as 
detected by Western blot. Values are given as mean; error bars represent the standard 
error of the mean. *P <.05; **P <.01. Gray bars: normal liver; black bars: tumor; white bars: 
adjacent to tumor.
and ductules albeit less pronounced than in the endothelial cells. Tie-2 
expression was strongly positive in HSEC and VEC in all groups but no 
expression was observed in hepatocytes, bile ducts and ductules. 
Discussion 
In this study we investigated the status of factors involved in angiogenic 
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Figure 5: Localization of Ang-1, Ang-2 and Tie-2 expression by immunohistology. Frozen 
52m section were immunohistologically stained as described in Materials and Methods.  
In normal liver, FNH and HCA, Ang-1 was expressed in hepatocytes only, whereas Ang-2 
and Tie-2 was expressed on vascular endothelial cells and sinusoidal endothelial cells. 
Ang-2 was less conspicuously expressed on sinusoidal endothelial cells in HCA than on 
vascular endothelial cells. Ang-1, Ang-2 and Tie-2 were also expressed on biliary 
structures in FNH. 
status of VEGF-A and VEGF-receptors R1 and R2, and Ang-1- and 2 and their 
receptor Tie-2. To determine possible alterations of the hepatic 
microvasculature in these tumors we also investigated CD34 and SMA 
expression. In histologically normal liver samples CD34 expression is only 
found on VEC and HSEC at the periportal margin while it is absent in HSEC in 
the rest of the lobule. In HCA we observed an increase of HSEC CD34 
expression in a patchy or diffuse distribution whereas the increased expression 
in FNH was concentrated in the central scar and its neighboring sinusoids. A 
similar distribution pattern of increased SMA expression was noted. Of the 
studied angiogenesis related factors, expression of VEGF-A, its receptors 
VEGFR-1, VEGFR-2 and Ang-2 with its receptor Tie-2 were all observed in the 
sinusoidal compartment, whereas Ang-1 was present in the epithelial 
component, the hepatocytes and biliary structures. In fact, the latter were 
found to express all studied angiogenic factors albeit in variable degrees.  
According to the current view of the control of angiogenesis, transition 
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from endothelial cell quiescence to activated endothelial cell is a prelude to the 
cascade of VEGF-A driven angiogenic sprouting. Endothelial cell quiescence 
is maintained by Tie-2 phosphorylation due to binding of Ang-1, whereas 
release of Ang-2 leads to competition with Ang-1 for Tie-2 and subsequent 
dephosphorylation that increases endothelial responsiveness to VEGF-A and 
possibly other angiogenic stimuli (5).  In the present study we observed, in 
both FNH and HCA, that neither Ang-2 gene nor protein levels were altered 
compared to their levels in normal liver tissue. In addition, changes of VEGF-A 
were undetectable in both tumor types.  
These findings imply that the VEGF-Ang/Tie2 pathway is likely not the key 
regulatory pathway for the tumor neovascularization in FNH and HCA. Instead, 
we observed an increased Ang-1/Tie-2 expression at the gene expression 
level in FNH and Ang-1 in HCA, while both factors are also readily visualized in 
both tumor types by immunohistology. Our data of increased gene expression 
of Ang-1 in FNH and HCA present the first confirmation of the studies by 
Paradis et al (6, 7). This suggests that the Ang-1/Tie2 system might play a 
regulatory role in the angiogenic activity in these tumors, the molecular 
consequences of which are by now unknown. We did find concurrent Tie-2 
up-regulation in FNH whereas Ang-2 showed no significant changes, which 
again emphasizes the possible specific induction of Ang-1/Tie-2 signaling in 
FNH and HCA. The multiple effects of Ang-1/Tie-2 have been summarized in 
several reviews (8-10). It is well established that Ang-1 plays a major role in 
maintaining vascular integrity by preventing endothelial cell death, recruitment 
of smooth muscle cells for stabilization of newly formed vessels, promoting 
differentiation of mesenchymal cells to vascular smooth muscle cells (reviewed 
in 10). The role of Ang-1/Tie-2 in vessel remodeling and angiogenesis has also 
been documented in several disease conditions, e.g., cardiac allograft 
vasculopathy, pulmonary hypertension, pathological hepatic vascular and 
lymphatic remodeling (11-14). In both tumor types included in the present 
study, new vessel formation is observed in variable abnormal patterns. FNH is 
characterized by dystrophic vessels containing severe myointimal hyperplasia, 
a morphological feature similar to Ang-1 induced allograft vasculopathy (11). 
The pathological vascular architecture due to transgenic expression of Ang-1 
in the liver, described in the experiments by Haninec et al. are reminiscent of 
the vascular changes observed in HCA (14). Another animal study showed 
that Ang-1 might modulate hepatic circulation resulting in abnormal vessel 
formation but also leading to nodular parenchymal changes similar to that seen 
in FNH (13).  
We and others have also found aberrant, increased expression of CD34 in 
HSEC showing dissimilar distribution patterns in FNH and HCA (15,16). This 
finding denotes that apart from the pathological vascular changes in these 
tumors HSEC has also become capillarized. The finding of increased 
expression of SMA, indicating activation of hepatic stellate cells and 
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myofibroblasts, not only underscores this process but probably reflects the 
effect of Ang-1/Tie-2 signaling on these cells. Hepatic stellate cells are 
currently recognized as the hepatic pericytes which are recruited to sites of 
vascular remodeling and new vessel formation under the influence of Ang-1 
stimulation (17).  A recent study reported an Ang-1 mediated angiogenic role 
of activated hepatic stellate cells in hepatic fibrosis (18). 
It is also recognized that Ang-1/Tie-2 signaling exerts its effects in a 
context-dependent manner (9). This was demonstrated in a recent study with 
two different cancer cell types. In tumor containing immature vessels Ang-1 
induced sprouting angiogenesis leading to tumor growth whereas inhibition of 
tumor growth was observed by Ang-1 enhanced maturation of vessels in a 
tumor containing highly mature vessels (19). These variable effects of Ang-1 
on different types of blood vessels should be taken into consideration when 
dealing with hepatic vasculature. HSEC and the sinusoidal space contain 
unique features regarding the endothelial cells characteristics, matrix 
constituents, the hepatic stellate cells, all of which have been reported to be 
involved in cellular responses to Ang-1/Tie-2 angiogenic activity. Cell-cell and 
cell-matrix contacts have recently been reported to be pivotal in Ang-1/Tie-2 
driven vascular remodeling (20), yet much is unknown about their exact 
interplay in the human liver. 
In conclusion, in these benign primary hepatic tumors the studied 
angiogenic growth factors appeared to be, directly or indirectly, related to other 
effects than inducing angiogenesis. Ang-1/Tie-2 induced vascular remodeling 
is probably an important pathway in hepatic tumor growth. As much is still 
unknown about the role of Ang-1 in hepatic angiogenesis, it is also rather 
premature to speculate on possible therapeutical options. For the benign 
hepatic tumors of the present study surgical resection is still the best 
therapeutic choice. However, cases of multiple adenomas might require 
another approach which could be provided by further exploration of the effects 
of Ang-1 on the dynamics of the hepatic vasculature.
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Abstract  
Background: Hepatocellular carcinoma (HCC) is one of the classical 
examples of inflammation-linked cancer and is described as a highly 
angiogenic tumor. Cyclooxygenases-2 (COX-2) is a potent mediator of 
inflammation and is considered to upregulate angiogenesis. 
Aim of the study: To correlate COX-2 expression with angiogenic factors 
relevant for sprouting angiogenesis. 
Patients and methods: Tissue samples of HCC and adjacent liver 
parenchyma of 21 patients with HCC in noncirrhotic liver and 34 patients with 
HCC in cirrhotic liver were analyzed for COX-2 expression at the mRNA level 
(real time RT-PCR) and at the protein level by Western blot and 
immunohistochemistry. The angiogenic factors VEGF-A, VEGFR-1, VEGFR-2, 
Ang-1, Ang-2 and Tie-2 were correlated with COX-2 levels separately in HCC 
and liver parenchyma. 
Results: At the protein level no correlation was found between COX-2 
expression and the levels of the angiogenic factors. At the mRNA level COX-2 
was correlated with mRNA levels of the angiogenic factors VEGFR-1, Ang-1 
and Tie-2 (Spearman’s rho .58, p<0.006). COX-2 mRNA and protein 
expression was higher in adjacent liver parenchyma than in HCC both in 
cirrhotic and noncirrhotic liver. COX-2 protein localized mainly in vascular and 
sinusoidal endothelial cells and in Kupffer cells. No correlation between COX-2 
mRNA and COX-2 protein was found. 
Conclusion: COX-2 expression is not associated with angiogenic factors 
which play a role in sprouting angiogenesis in clinically detectable HCC. 
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Introduction: 
More than 80% of hepatocellular carcinomas (HCC) are associated with 
chronic infection caused by either hepatitis B or C virus.(1) In well-developed 
countries with a high incidence of obesity and diabetes mellitus the risk of 
developing HCC rises proportionally with increasing body mass index (BMI) 
and the duration of diabetes.(2;3) These conditions are frequently associated 
with non-alcoholic steatohepatitis (NASH).(4;5) The common denominator in 
viral hepatitis associated liver diseases and NASH is presumed to be the 
chronic inflammation leading to fibrosis and cirrhosis and ultimately to HCC. 
HCC is thus one of the classical examples of inflammation-linked cancer.(6)
The cyclooxygenases-2 (COX-2)- prostanoid pathway plays a pivotal role in 
inflammation as well as in the pathophysiology of many liver diseases and 
associated conditions, e.g. fibrosis, portal hypertension, cirrhosis and HCC.(7)
COX-2 is an inducible immediate-early gene originally found to be induced by 
various stimuli including mitogens, cytokines and growth factors.(8) COX-2 
might favor tumor growth by various mechanisms including stimulation of 
angiogenesis, evasion of apoptosis and propensity to metastatic behavior and 
invasion. COX-2 inhibitors can block these mechanisms by various pathways 
and selective COX-2 inhibitors have been evaluated for their effect on HCC 
cell growth and invasion using animal models of hepatocarcinogenesis.(9;10)
Apart from the development of HCC in cirrhotic liver, HCC can also arise 
in noncirrhotic livers with normal histology and no signs of inflammation or 
previous viral hepatitis. A common characteristic of both types of HCC is the 
highly vascularized nature, which is one of the hallmarks for diagnosing HCC. 
The occurrence of both types of HCC in humans offers a unique opportunity to 
study the possible relation between inflammation and angiogenesis, in which 
angiogenic characteristics can be analyzed in the presence (cirrhotic HCC) or 
absence (noncirrhotic HCC) of chronic inflammation. Unraveling of the 
underlying mechanisms might offer in the future more efficacious treatment 
modalities both for (chemo)prevention and possibly also for treatment of 
already established HCC.  
 The aim of the present study is to correlate COX-2 expression with the 
expression of angiogenic factors in human HCC in cirrhotic and noncirrhotic 
livers.  We investigated gene and protein expression levels of COX-2, 
VEGF-A, VEGFR-1 (Flt-1) and VEGFR-2 (KDR), and Angiopoietin (Ang)-1, 
Ang-2, and their receptor Tie-2 using quantitative RT-PCR and Western blot 
analysis in HCC, adjacent liver parenchyma and normal liver parenchyma. The 
cellular localization of COX-2 was studied by immunohistology. 
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All (anonymised) tissue samples were collected in the University Medical 
Center Groningen, the Netherlands and were processed according to national 
guidelines of the Dutch government. Tissue samples of 55 HCC patients were 
included; 21 noncirrhotic HCC were obtained from partial liver resection 
specimens and 34 cirrhotic HCC were obtained from liver explants during liver 
transplantation. A sample of adjacent, non-tumorous liver tissue was also 
included in the study. None of the HCC patients had been previously treated 
by local ablation, chemoembolisation or chemotherapeutic drugs before 
surgery. We also included 9 samples of histologically normal liver collected 
from surplus material of donor livers, or from partially resected livers from 
patients with a hemangioma in the liver or a traumatic liver rupture.  
RNA extraction and real-time reverse transcription polymerase chain 
reaction (RT-PCR)
Total RNA was isolated with the RNAeasy Mini Kit (Qiagen, Leusden, 
Netherlands) with subsequent DNA removal using the RNase-free DNase set 
(Qiagen), both according to the protocol of the manufacturer. RNA was 
analyzed qualitatively by gel electrophoresis and quantitatively with Nanodrop 
ND-100 spectrophotometer (NanoDrop Technologies, Rockland, DE, USA). 
Reverse transcription and real-time PCR were performed as described 
previously.(11) Briefly, one microgram of total RNA was used for the synthesis 
of first-strand cDNA and 10ng cDNA was used for each PCR reaction. Exons 
overlapping primers and minor groove binder (MGB) probes were purchased 
as Assay-on-Demand from Applied Biosystems (Nieuwekerk a/d IJssel, The 
Netherlands): housekeeping gene GAPDH (assay ID Hs99999905_m1), 
COX-2 (assay ID Hs00153133_m1), VEGF (Hs00173626_m1), EGFR-1 
(Hs00176573_m1), VEGFR-2 (Hs00176676_m1), Tie2 (assay ID 
Hs00176096_ml), Ang-1 (assay ID Hs00181613_ml), Ang-2 (assay ID 
Hs00169867_ml). Control samples of distilled water and at random selected 
samples of RNA not subjected to reverse transcriptase were consistently found 
to be negative. TaqMan RT-PCR was performed in an ABI PRISM 7900HT 
Sequence Detector (Applied Biosystems) with the following cycling conditions: 
2 min at 50°C, 10 min at 95°C, and 40 two-step cycles of 15 s at 95°C and 60 s 
at 60°C. Triplicate real-time PCR analyses were executed for each sample, 
and the obtained threshold cycle values (Ct) were averaged. Gene expression 
was normalized to the expression of the housekeeping gene GAPDH, yielding 
the relative gene expression level.  
Western blot 
Of each frozen tissue block, twenty 5m thick tissue slices were lysed in 
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radioimmunoprecipitation assay (RIPA) buffer [50 mM Tris HCl, pH 7.4, 150 
mM NaCl, 1% nonidet P-40, 0.25% Na-deoxycholate, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 1 mM sodium fluoride, 1 mM sodium 
orthovanadate, 100 g/ml phenylmethylsulfonyl fluoride (PMSF), 1 g/ml 
aprotinin (Sigma), and 1 g/ml leupeptin (Roche), and 1 g/ml pepstatin 
(Roche)]. Cell debris was removed by centrifugation at 10,000g for 15 minutes, 
and protein concentration was measured using pyrogallol red-molybdate 
solution. Indicated amounts of lysates were separated on sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to 
nitrocellulose membranes (0.45m, Bio-Rad laboratories; Hercules, CA). The 
membranes were next probed with mouse anti-COX-2 1:500 (BD Biosciences 
Pharmingen, #610204) diluted in 5% non-fat milk/TBST. Then followed by 
incubation with peroxidase-labeled rabbit anti-mouse Ig (DAKO, 1:1000 diluted 
in 5% non-fat milk/TBST ) and treated with an enhanced chemiluminescent 
substrate for detection of HRP (Amersham Life Science, London, UK). After 
stripping with 25mM glycine/1%SDS (PH=2.0), ß-actin was detected on the 
membrane, using the same method (mouse anti- ß-actin, Abcam, ab8226). 
Protein expression observed as electrophoretic bands was quantified using 
image analysis software (Quantity One, Bio-Rad), which calculated the volume 
of bands (intensity x mm2). The COX-2 volume of each sample was divided by 
the control (ß-actin), yielding the protein expression value presented. The 
bands of COX-2 protein were located at  about 70KD as expected according 
to the datasheet of the antibody. 
Immunohistological examination of COX-2 expression  
4m tissue sections were deparaffinized and treated with  0.08% H2O2
for 30 minutes to block endogenous peroxidase. Slides were incubated with 
mouse anti-COX-2 (BD Biosciences Pharmingen, #610204) 1:50, diluted in 
1%BSA/PBS, at 4oC overnight, followed by incubation with horseradish 
peroxidase-conjugated rabbit anti-mouse Ig and goat anti-rabbit Ig (DAKO), 
both 1:100 diluted in 1%BSA/1% albumin/PBS. Diaminobenzidin was used to 
develop the staining reaction and nuclear counterstaining was performed with 
hematoxylin.  As a positive control a sample of a colon adenocarcinoma was 
included. 
Analysis of correlation between COX-2 protein and mRNA level 
In order to correlate the COX-2 mRNA expression with the corresponding 
COX-2 protein levels the Pearson correlation coefficient was calculated 
separately for HCC and liver parenchyma. To get a more detailed picture of 
this correlation we calculated the COX-2 protein:COX-2 mRNA ratio for each 
individual case; this method has been used for identification of the strength  of 
correlation of mRNA expression and protein level of individual genes by Pradet 
et al.(12) This ratio is depicted in a scatter plot as arbitrary units (protein:mRNA 
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ratio) on the y-axis and the individual cases on the x-axis. 
Correlation of COX-2 with Ang-2:Ang-1 ratio 
Although in many tumors both Ang-1 and Ang-2 are elevated, the 
pro-angiogenic state of hypervascular tumors is characterized by an 
overexpression of Ang-2 in relation to Ang-1 thus creating a shift in the 
Ang-2:Ang-1 ratio in favor of Ang-2.(13) Therefore we analyzed the correlation 
between COX-2 mRNA/protein expression and the Ang-2:Ang-1 ratio 
separately in HCC and liver parenchyma.   
Statistical analysis 
Quantitative data were expressed as median and interquartile range (IQR). 
A two-tailed nonparametric test was used for comparison of groups; either the 
Mann-Whitney-U test for non-related samples (comparison between cirrhotic 
and noncirrhotic samples) or the Wilcoxon test for related samples 
(comparison between tumor and adjacent liver tissue). Correlation statistics 
between COX-2 and angiogenic variables were performed using the 
non-parametric Spearman’s rho test. For all statistical analyses, the level of 
significance was set at 0.05. 
Results 
Correlation of COX-2 gene expression and protein level with angiogenic 
factors 
Table 1 shows that COX-2 mRNA levels in HCC in both cirrhotic and 
noncirrhotic liver were significantly correlated with mRNA levels of VEGFR1, 
Ang-1 and Tie-2. The strongest correlation was obtained between COX-2 
mRNA and Tie-2 mRNA; Spearman’s rho was around .80. Only in HCC in 
noncirrhotic liver a significant correlation between COX-2 mRNA and VEGFR2 
mRNA was obtained (rho .72, p < 0.001). COX-2 protein was correlated with 
VEGFA mRNA in noncirrhotic HCC, whereas in cirrhotic HCC the mRNA levels 
of COX-2 were correlated with VEGFA in the tumor. No correlations were 
found between COX-2 expression and protein levels of the angiogenic factors 
(data not shown). We found that neither COX-2 mRNA nor COX-2 protein 
correlated with protein levels of the angiogenic factors. The Ang-2:Ang-1 ratio 
was not correlated with COX-2 protein or mRNA levels in normal liver (data not 
shown) or in liver parenchyma adjacent to HCC in both cirrhotic and 
noncirrhotic liver (table 1). In HCC tumor tissue no statistically significant 
correlation between the Ang-2:Ang-1 ratio and COX-2 mRNA/protein was 
found except for  a negative correlation between the Ang-2:Ang-1 ratio and 
COX-2 mRNA in noncirrhotic HCC (rho -.58, p = 0.006, Table 1)  
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Table 1. Correlation between COX-2 mRNA and protein level with mRNA level of various 
angiogenic factors. Spearman’s rho and p-value are presented in tumor and adjacent 
cirrhotic and noncirrhotic liver separately. The significant correlations are represented in 
bold. 
Non-cirrhotic liver Cirrhotic liver 
COX-2 mRNA COX-2 protein COX-2 mRNA COX-2 protein
mRNA level 
angiogenic 
factor  tumor adjacent tumor adjacent tumor adjacent tumor adjacent
VEGFA tumor 0.29  .61    .04  .37   .03   0.08 
VEGFA adjacent   -0.15   -0.2  .44    .04   0.06 
VEGFR-1 tumor .58  .006   0.18  .49  .003   0.33 
VEGFR-1 
adjacent 
  -0.19   0.45   0.07   -0.09 
VEGFR-2 tumor .72  .001   -0.31   0.26   0.1 
VEGFR-2 
adjacent 
  0.51   -0.26   0.12   -0.3 
Ang-1 tumor .60  .004   -0.21  .62  .001   0.33 
Ang-1 adjacent   0.05   -0.34  .53  .009   -0.01 
Ang-2 tumor 0.1   -0.53   0.2   -0.08 
Ang-2 adjacent   -0.24   -0.02  .41   .05   -0.12 
Tie-2 tumor .82  .001   -0.25  .76  .001   0.36 
Tie-2 adjacent   -0.32   -0.56   0.23   -0.09 
Ang-2:Ang-1 
tumor 
-.58 .006   -0.14   -0.23   -0.31 
Ang-2:Ang-1 
adjacent 
  -0.21   0.12   0.1   0.03 
COX-2 expression in normal liver parenchyma, tumor-adjacent liver 
parenchyma and HCC in cirrhotic versus noncirrhotic liver 
No difference in COX-2 mRNA and COX-2 protein expression was found 
in normal liver parenchyma and parenchyma adjacent to tumor (Fig 1,2).  
COX-2 expression was observed in both vascular and sinusoidal endothelial 
cells as well as in Kupffer cells in normal liver and in parenchyma adjacent to 
HCC; no expression was found in hepatocytes or in cholangiocytes (Figure 3). 
A comparison between COX-2 mRNA and protein expression in cirrhotic 
versus noncirrhotic HCC revealed no differences, although a trend towards 
higher protein levels in HCC in cirrhotic liver was seen (p = 0.07, Fig 1/2). 
Using immunohistology, COX-2 expression in HCC was mainly found in 
endothelial cells lining the sinusoid-like spaces in the tumor but less 
conspicuous than in vascular endothelial cells at the interface between tumor 
and adjacent liver parenchyma. (Figure 3).  
As a positive control of COX-2 immunohistological staining we included a 
colon carcinoma sample which was strongly positive (Figure 4). 
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COX-2 expression in HCC compared with tumor-adjacent liver 
parenchyma 
Liver parenchyma adjacent to the tumor demonstrated a higher COX-2 
expression than the tumor, both at the mRNA and protein level and both in 
cirrhotic and noncirrhotic liver (Figure 1/2). Median COX-2 mRNA level in 
tumor-adjacent liver parenchyma was about tenfold higher than in the tumor in 
noncirrhotic liver (p = 0.01). In cirrhotic liver, tumor-adjacent parenchyma had a 
six-fold higher COX-2 mRNA content (p < 0.001). Protein levels of COX-2 were 
approximately 370 fold higher in adjacent liver parenchyma as compared to 
HCC in noncirrhotic liver. In cirrhotic liver, adjacent parenchyma had a 30% 
higher COX-2 protein level (p < 0.02) than the tumor. Although median COX-2 
expression in HCC was less than in the surrounding parenchyma, individual 
cases demonstrated variable results as can also be seen in the Western blots 







Figure 1.  Box plots 
representing relative gene
expression of COX-2 in 
normal liver (n = 9), HCC in
non-cirrhotic liver (n = 21) 
and liver parenchyma 
adjacent to HCC (n = 11), 
HCC in cirrhotic liver (n = 
34) and liver parenchyma 
adjacent to HCC (n = 23), 
as determined by 
quantitative RT-PCR. (The
horizontal line inside the 
box and the box represent
the median value and the 
interquartile (25 – 75%) 
range respectively. *P
<0.05)
Figure 2.  Box plots 
representing the relative 
protein level of Cox-2 in 9 
normal livers, 11 matched
HCC/adjacent parenchyma
of noncirrhotic livers, and 
22 matched HCC/adjacent
parenchyma of cirrhotic 
livers. (The horizontal line 
inside the box and the box
represent the median 
value and the interquartile
(25 – 75%) range 
respectively. *P <0.05)
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Correlation of COX-2 mRNA expression and protein level 
A non-significant (p=0.65) correlation between COX-2 mRNA expression 
and COX-2 protein level in HCCs was found (Pearson rho -.81). Also no 
correlation was found when analyzing COX-2 protein and mRNA in liver 
parenchyma from both normal livers and HCC tumor livers (p=.14, Pearson rho 
0.23). In scatter plots (Figure 6; upper panel adjacent parenchyma; lower 
panel HCC) the correlation between the expression levels of COX-2 mRNA 
and the corresponding protein is depicted as protein:mRNA ratio (arbitrary 
units) for the individual cases. The data demonstrate a poor correlation (r = 
0.18 in HCC and r = 0.23 in liver parenchyma, both p > 0.05) between COX-2 
mRNA and protein level. As can be seen in figure 6 (lower panel) protein 
expression can vary between around 0 (first case lower left corner) and more 
than 37,000 (last case upper right corner) in relation to a given mRNA 
expression level in HCC. In liver parenchyma (both normal and tumor-adjacent) 
the COX-2 protein:COX-2 mRNA ratio has a lower range, varying from  100 to 
more than 7,000 (Figure 6 upper panel)  
Figure 3: COX-2 
immunostaining on HCC 
(upper left) and adjacent 
liver parenchyma (lower 
right). COX-2 expression 
is present on endothelial 
cells (arrows) at the 
interface between HCC 
and non-tumorous liver 
parenchyma. In the liver 
parenchyma COX-2 
expression is mainly 
present in Kupffer cells 
and some inflammatory 
cells. Note the absence 
of staining in 
hepatocytes and tumor 
Figure 4: COX-2 immunostaining on 
coloncarcinoma as a positive 
control.
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Figure 5. Representative samples of Western blot of COX-2 in matched (pairs of 11 
noncirrhotic (upper panel) and 8 cirrhotic (lower panel) samples of HCC and 
tumor-adjacent liver parenchyma. (Adj: tumor-adjacent liver parenchyma; T: tumor 
(HCC)). 
Figure 6. Correlation between COX-2 mRNA (real time RT-PCR) and corresponding 
COX-2 protein level (Western blot) in liver parenchyma (right panel) and hepatocellular 
carcinoma (left panel). Samples of parenchyma were obtained from normal liver (n = 9), or 
parenchyma adjacent to HCC in noncirrhotic liver (n = 11) or cirrhotic liver (n = 22). Tumor 
samples (left panel) were obtained from cirrhotic or noncirrhotic HCC. The horizontal lines 
represent the median values.  (: normal liver, : noncirrhotic liver, : cirrhotic liver) 
Discussion 
In this study we tried to evaluate in human HCC whether COX-2 -an 
important mediator of inflammation- is related to the expression of factors 
which have a role in tumor angiogenesis. Four main conclusions can be drawn 
from this study.  
First, we were not able to identify a correlation between COX-2 protein 
and the protein levels of the angiogenic factors neither in the tumor nor in 
adjacent liver parenchyma. This finding holds true both for cirrhotic and 
noncirrhotic liver. Translation of the results of this correlative study into a 
conclusion of a causal relation between COX-2 and angiogenic factors should 
be done very cautiously, if at all. However, this lack of correlation suggests that 
Case1 Case2  Case3  Case4   Case5   Case6   Case7   Case 8    Case9  Case10  Case11 
Adj T   Adj  T Adj T  Adj T   Adj  T  Adj  T  Adj  T  Adj  T  Adj  T  Adj T  Adj  T
Cox-2 
-actin
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COX-2 protein is not pivotal as a mediator of angiogenesis.  
The second conclusion is that although COX-2 mRNA expression is 
positively correlated with the expression of the VEGF-Receptor1 (VEGFR-1) 
and Ang-1 and Tie-2 in HCC this also does not support an important role for 
COX-2 as an initiator of angiogenesis. This is because only a positive 
correlation with the vessel stabilizing growth factor Ang-1 was found and not 
with the vessel destabilizing growth factor Ang-2. Thus, this finding suggests 
that COX-2 expression in HCC occurs at a stage in which vessel stabilization, 
more than destabilization, is the prominent feature. Current knowledge with 
respect to angiogenesis states that Ang-1, which is widely expressed in human 
tissues, constitutively activates Tie-2, which is almost exclusively expressed in 
endothelial cells, and thereby maintains blood vessel quiescence.(14;15) Ang-2 
is mainly produced by endothelial cells and is active at sites of vascular 
remodeling like the female reproductive organs –especially placenta- and 
certain tumors.(14;15) Upregulation of Ang-2 results in binding to Tie-2 and 
destabilization of vessels which subsequently can develop in two ways 
depending on the presence of other cytokines; in the presence of 
proangiogenic cytokines, like VEGF, angiogenesis will occur, whereas in the 
absence of proangiogenic activity vessel regression will follow. When we apply 
the concepts of the angiogenic balance to the findings in the present study, an 
active role for COX-2 as a mediator of angiogenesis in human HCC is 
questionable. The reason is that although a positive correlation between 
COX-2 and VEGF-A and VEGFR-1 was found (suggesting preparation for 
angiogenesis), it is unlikely that VEGFA can exert its angiogenic action 
because concomitantly COX-2 is positively correlated with Ang-1/Tie-2 
(favoring vessel quiescence) and COX-2 is not correlated with Ang-2 
expression, the upregulation of which is a prerequisite for vessel 
destabilization and angiogenesis. The pro-angiogenic switch, characterized by 
a Ang-2:Ang-1 ratio in favor of Ang-2, has been found in many tumor types 
including HCCs.(13) But even by analyzing this pro-angiogenic Ang-2:Ang-1 
ratio in relation to COX-2 expression in HCC and adjacent liver parenchyma 
we could not obtain a positive correlation, again suggesting that COX-2 is not 
acting as a pro-angiogenic mediator via the Ang-1/2 and Tie-2 system. 
Although causative relations cannot be drawn from this correlative study the 
suggestion is raised that COX-2 is not a mediator in angiogenesis because it is 
not only positively correlated with the expression of the angiogenic cytokine 
VEGFA and its receptor (VEGFR-1) but also with that of the vessel stabilizing 
Ang-1/Tie-2 system. 
The third conclusion that can be drawn from this study is that the chronic 
inflammation in cirrhotic liver parenchyma is not associated with an increased 
COX-2 expression. The current dogma describes that COX-1 is constitutively 
expressed and COX-2 is only expressed as a result of induction by a wide 
range of stimuli.(16) In a recent autopsy study on trauma victims, this concept 
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was seriously questioned, because several healthy tissues, including the 
normal liver were shown to express COX-2.(17) We also found COX-2 
expression in normal liver parenchyma; this was comparable to COX-2 
expression in liver parenchyma adjacent to HCCs. In parenchyma adjacent to 
HCC we found that COX-2 expression was even higher than in HCC itself. Our 
data are in agreement with findings of Morinaga et al. who found a 2.5- fold 
higher COX-2 mRNA expression in adjacent liver parenchyma as compared to 
HCC.(18) In their study COX-2 protein expression -determined by 
immunohistochemistry- seemed to parallel mRNA expression although it was 
evaluated in only 8 of 22 samples.  
The fourth finding is the strongly inconsistent correlation between COX-2 
and angiogenic factors with respect to mRNA and protein levels. At the mRNA 
level a positive and significant correlation between COX-2 and the angiogenic 
factors VEGFR-1, Ang-1 and Tie-2 was found. Thus one would also expect a 
comparable correlation between COX-2 and the same angiogenic factors at 
the protein level. However, at the protein level none of the angiogenic factors 
correlated with COX-2 protein expression. It turned out that COX-2 mRNA 
levels were not correlated with COX-2 protein levels both in liver parenchyma 
and in HCCs. We more specifically analyzed this discrepancy by calculating 
the ratio COX-2 mRNA:COX-2 protein level for the individual samples of both 
liver parenchyma and HCC as suggested previously.(12) These ratios revealed 
a range of 0–7,000 and 0–37,000 in liver parenchyma and HCC respectively. 
This discordance between COX-2 mRNA and protein level is likely to be 
explained by post-transcriptional mechanisms, like transcript decay and 
translation rate, but also by post-translational modifications which determine 
protein turnover and thereby protein expression levels.(19) In a pivotal study, 
analyzing 106 genes of the yeast S. cerevisiae, Gygi et al. found an overall 
good correlation between mRNA and protein level, but  in a subset of 73 low 
abundance proteins the correlation was weak.(20) In that study a non-significant 
Pearson correlation coefficient as low as 0.10 was found for the lowest 
abundance proteins.(20) For some genes these authors found a more than 
20-fold difference in protein expression for mRNA levels of the same value. 
They concluded that mRNA transcript levels provide little predictive values for 
the level of protein expression, especially for the low abundance proteins to 
which COX-2 belongs. Also in humans highly discrepant results between 
mRNA and protein expression were encountered; in a study of human lung 
adenocarcinomas only 17% (28/165) of the analyzed proteins demonstrated a 
significant correlation between mRNA and protein levels within the same 
tumor.(21) Another study on 47 human colon carcinoma samples revealed no 
correlation between mRNA levels and protein levels of dihydropyrimidine 
dehydrogenase, the enzyme metabolizing the cancer drug 5-fluorouracil.(22)
Taken together, mRNA abundance does not necessarily translate into the 
detection of the corresponding protein with the currently available techniques 
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and conclusions based solely on protein expression even if in combination with 
mRNA expression should be drawn cautiously.(12)
The question rises whether these precautions also apply for COX-2 
expression in HCC. Several pathways regulate post-transcriptional COX-2 
expression, many of which are of importance in HCC as well.(23;24) Alterations 
in these pathways might have an influence on COX-2 expression. It is also 
important to realize that COX-2 protein has a short half-life. In various cell lines 
COX-2 protein degradation varies from 2 to 7 hours (16)  Also relevant in this 
respect is the recent discovery of a second pathway for COX-2 protein 
degradation which can be stimulated by the addition of the substrate 
arachidonic acid. (25) 
From this study in human HCCs we conclude that COX-2 is expressed to 
a similar extent in cirrhotic and noncirrhotic background. Additionally, we 
conclude that COX-2 mRNA expression in HCC is correlated with angiogenic 
factors playing a predominant role in vessel stabilization and as such it is 
unlikely that COX-2 is associated with sprouting angiogenesis.  With the 
current working concept of the angiogenic balance, it is unlikely that COX-2 
acts as an angiogenic mediator in advanced human HCC.  
A further unraveling of transcriptional and post-transcriptional processing 
of COX-2 will hopefully shed light on the discrepancies between COX-2 mRNA 
and COX-2 protein levels. The clinical usefulness of COX-2 inhibitors 
especially in the setting of chemoprevention for the development of human 
HCC can only be based on randomized clinical trials since the precise 
regulatory mechanisms of COX-2 are far from elucidated. (26-28)
Although the concept of the angiogenic balance is considered to be 
essential for tumor vessel development, tumor heterogeneity and angiogenic 
escape pathways exist which make tumor angiogenesis far more complex and 
less predictable and could probably also explain unresponsiveness of some 
tumor types to anti-angiogenic treatment.(29;30)
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Summary  
Hepatocellular carcinoma (HCC) is the fifth most common tumor 
worldwide, and the third cause of cancer-related death.1 The grave prognosis 
of HCC is a consequence of the absence of adequate curative options. 
Angiogenesis is today considered the most important mode of tumor growth 
associated neovascularization and hence an interesting target for therapy. 
Insight in the molecular angiogenic features of HCC is pivotal for selection of 
the proper drug class and treatment regimen tailored for the disease.  
The angiogenic status of human liver tumors is not investigated to its full 
extent. In addition, HCCs can arise in cirrhotic liver but also in non-cirrhotic 
liver. As the molecular program underlying angiogenic sprouting is subject to 
microenvironmental control, the question arises whether the angiogenic status 
in HCC occurring in a cirrhotic liver is different from that in a non-cirrhotic liver. 
In addition to HCC, there are benign tumors in the liver, including focal nodular 
hyperplasia (FNH) and hepatic adenoma. FNH accounts for 8% of all primary 
liver tumors and is the second most common benign liver tumor after 
hemangioma.2 Hepatic adenoma is rare, but malignant transformation has 
been described.3 Similar to HCC, also for these tumors limited knowledge on 
the cellular and molecular status underlying tumor growth associated 
neovascularization is available. In this thesis research, we aimed to study the 
angiogenic status of these various types of liver tumors. We studied the 
cellular activation and proliferation status, and the accompanying levels and 
profiles of genes and proteins that are currently considered to be essential for 
the initial stages of angiogenesis as well as for vascular maturation.
In chapter 2, we analyzed in HCC in cirrhotic and non-cirrhotic livers 
endothelial cell dynamics (proliferation and apoptosis), microvascular density 
(MVD), and vessel maturation status (pericytes coverage) as indirect markers 
of angiogenesis, and correlated these features with tumor vascularization on 
dynamic contrast enhanced CT and with prognosis. We found that in both 
conditions endothelial cell proliferation and apoptosis were low in tumor 
microvessels, and that the majority of tumor vessels were covered by pericytes. 
MVD was negatively correlated with contrast wash out in the portal venous 
phase of CT scanning. In HCC in non-cirrhotic livers for which patients were 
treated by liver resection, a high MVD was associated with a better prognosis. 
Endothelial cell dynamics in these tumors predominantly demonstrated 
quiescence and tumor microvessels mainly exhibited characteristics of mature 
vessels suggesting that angiogenic sprouting is not a hallmark of clinically 
detectable HCCs. 
Based on the observation in chapter 2 that the tumor vasculature 
presented itself with a mature phenotype, we hypothesized that tumor 
neovascularization via angiogenic sprouting is not overtly active in HCC. In
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chapter 3, we quantified gene and protein expression of members of the 
VEGF and Angiopoietin (Ang) systems and studied their cellular localization, 
both in HCC in non-cirrhotic and cirrhotic livers. We employed real-time 
RT-PCR, Western blot, and immunohistology, and compared the outcome with 
highly angiogenic human renal cell adenocarcinoma (RCC). Both HCC from 
non-cirrhotic and cirrhotic livers expressed VEGF-A and its receptors to a 
similar extent as normal liver. The Ang-1 expression was slightly increased 
compared to normal liver, while the Angiopoietin receptor Tie-2 was strongly 
downregulated in the tumor vasculature. Ang-2 expression was downregulated 
in both types of HCC compared to normal liver. In contrast, in RCC VEGF-A 
levels were one order of magnitude higher, and (endothelially expressed) 
Ang-2 was over 30 fold increased compared to expression in normal kidney, 
while Ang-1 expression was decreased.  These data imply that in HCCs, 
irrespective whether they arise in a non-cirrhotic or cirrhotic liver, the tumor 
vascularization does not originate from Ang/Tie-2 based vascular 
destabilization and VEGF driven angiogenic sprouting.  However, increased 
CD31 expression and morphological changes representative of sinusoidal 
capillarization in tumor associated capillaries indicate that vascular remodeling 
is taking place in HCC.  
Besides malignant liver tumors, liver cells can give rise to benign tumor 
growth. The data obtained in chapter 3 triggered the question whether these 
tumors exhibit a similar angiogenic profile.  
In chapter 4 we therefore studied gene expression and protein profiles of 
VEGF, its receptors VEGFR-1 and 2, and of the Angiopoietins and their 
receptor Tie-2 in FNH and hepatic adenomas (HCA), of which several 
subtypes exist.4 Immunohistology was performed for the cellular localization of 
the proteins and we also studied the expression pattern of CD34 and alpha 
smooth muscle actin (SMA). We compared these profiles with those of 
normal liver samples. We found an increased expression of both CD34 and 
SMA in FNH and HCA, each with its own pattern. We observed no changes in 
expression of VEGF-A, VEGFR-1, and VEGFR-2 in all types of tumors. In 
contrast, both FNH and HCA were characterized by increased expression of 
Ang-1, concurrently with increased Tie-2 in FNH, while in both tumor types 
Ang-2 levels were similar to those in normal liver samples. The up-regulation of 
Ang-1 in FNH and HCA along with the various morphological vascular 
abnormalities which characterized FNH and HCA were similar to the vascular 
features that have been described in animal models following induction of 
Ang-1/Tie-2 signaling. Our findings of the absence of Ang-2/Tie-2 
overexpression and the unaltered VEGF-A status in HCA and FNH implies that 
in these benign tumors the VEGF-A/Ang-Tie2 angiogenic pathway is not the 
major pathway for tumor vascularization. Based on our results we suggested 
the possibility of an Ang-1/Tie-2 driven vascular remodeling. 
The last research chapter is dedicated to COX-2, an inducible 
95
Chapter 6                                                                        
96
immediate-early gene induced by various stimuli, that can stimulate 
angiogenesis and is associated with tumor growth, invasion and metastasis.5,6
Targeting COX-2 or molecules downstream of COX-2 has been proposed as a 
strategy in the prevention and treatment of solid tumors.7,8 In this chapter 5,
we quantitatively examined the expression of COX-2 mRNA and protein in
normal livers and in the HCCs using real time RT-PCR and Western blot, 
respectively, and compared COX-2 expression with the expression of 
angiogenic factors (VEGF, VEGFR-1, VEGFR-2, Ang-1, Ang-2, and Tie-2). We 
showed that the COX-2 mRNA levels were lower in both cirrhotic and 
non-cirrhotic HCC as compared to normal livers and corresponding adjacent 
non-tumorous tissues. COX-2 mRNA expression in HCC was significantly 
correlated with angiogenic factors which mainly have a role in vessel 
stabilization. These results suggest that COX-2 may not exert a prominent role 
in tumor angiogenesis and progression of HCC.  
Altogether, we demonstrated that in HCC originating in cirrhotic and in 
non-cirrhotic livers, endothelial cells of tumor vessel are predominantly 
quiescent, with the tumor microvessels exhibiting characteristics of mature 
vessels. HCCs as well as benign hepatic tumors do not exhibit robust 
angiogenic sprouting activity driven by VEGF-A and the Angiopoietin/Tie-2 
system. Also COX-2 does not seem to play a predominant role in vessel 
destabilization, a prerequisite for angiogenic sprouting. These observations 
have important implications for therapeutic decision making regarding 
anti-angiogenesis based therapy of HCC, as will be discussed below. 
General discussion and future perspectives 
Problems in therapeutically targeting the tumor vasculature 
It is a revolution in the treatment of tumors to therapeutically target the 
tumor vasculature, which is considered genetically stable and hence less 
adaptive to pharmacological pressure to induce drug resistance. To various 
extents, all tumor cells are dependent on a blood supply that delivers oxygen, 
nutrition and growth factors and takes away waste products. Therefore, 
therapy aimed to attack the tumor vasculature represents a promising strategy 
for the treatment of cancer and will most likely exhibit its clinical potential in 
combination with established standard tumor therapy in the future.9
 In 2007, ten new drugs with anti-angiogenic activity have been approved 
by the FDA for the treatment of cancer, and at least 43 other anti-angiogenic 
drugs were in clinical trials in the United States.10 However, in both preclinical 
and clinical settings, the resistance to anti-angiogenic therapy is a major 
problem. The benefits from anti-angiogenic drugs are at best transitory and are 
followed by tumor re-growth and progression.11 The large degree of 
heterogeneity in endothelial behavior in different tumor microenviornmental 
conditions is likely to play an important role in this resistance. The presence of 
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numerous different angiogenic molecules in a tumor results in a system with a 
variety of redundancy pathways. Additionally, the capacity to employ other 
mechanisms than VEGF- or FGF-driven sprouting angiogenesis to acquire a 
blood supply, such as intussusceptive angiogenesis, recruitment of endothelial 
progenitor cells, vessel co-option, vasculogenic mimicry and 
lymphangiogenesis, provides a tumor with even more possibilities to evade 
anti-angiogenic therapy.12,13 Furthermore, there is no biomarker which can 
identify the patients who will benefit from a certain anti-angiogenic drug. Below, 
some of these issues will be addressed in more detail, with special reference 
to liver tumors.  
In vitro and animal models do not mimic the status in human tumors 
Until now, the majority of cell biological concepts in tumor growth related 
angiogenesis have been derived from animal studies. Many of these studies 
employ injection of tumor cell suspensions in a site that is often chosen to 
analyze specific parameters of interest. For example, for intravital microscopy 
to monitor on line neovascular sprout formation and e.g., leakiness of tumor 
vasculature or effects of drugs thereon, skin-fold window chamber assays are 
extensively used.14 For many studies on the anti-tumor effects of 
anti-angiogenic drugs, s.c. inoculated tumor cell models are utilized as they 
provide an easy means to analyze the effects of the drugs on tumor outgrowth 
rate. Furthermore, many pre-clinical tumor models make use of human tumor 
cell growth in an immune compromised environment, thereby neglecting the 
contribution of immune cells to the neovascularization process. Although the 
pre-clinical studies have provided a solid foundation for the understanding of 
many cellular and molecular concepts underlying tumor driven angiogenesis, 
there is an urgent need to either confirm these concepts in human tumors, or to 
challenge or re-define them. Only by this means, the gap between the 
pre-clinical successes and clinical disappointments of tumor vascular directed 
therapeutics can be bridged. 
Animal tumors at early growth represent a condition of synchronized tumor 
vascular growth. Patients often present in the clinic with excessive tumor 
burden that is accompanied by intrinsic variations in tumor cell proliferation 
status and oxygen demand, and consequent differences in demand for 
neovascularization as a means to support further tumor growth. As a 
consequence, tumor samples obtained from patients are both highly variable 
with regard to the location within the bigger tumor and the time frame between 
the angiogenic switch and obtaining the biopsies. Patient material is hence per 
definition heterogeneous, yet the only source to study the pathogenetic 
concepts derived from animal models and their applicability in human tumors. 
Since this heterogeneity will be a constant feature in which future therapies will 
have to be applied, a thorough knowledge of the angiogenic status of human 
tumors is a prerequiste for future success.  
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Technological issues about analyzing the angiogenic status of (liver) 
tumors 
The studies described in this thesis address the important issue of the 
angiogenic status of a malignant liver tumor  (HCC), and a number of benign 
liver tumors in patients. Understanding the molecular make up that drives the 
tumor vascularization process in these tumors may provide important clues for 
rational drug development and drug treatment schedules if surgery is not a 
therapeutic option. It can enrich our knowledge about the “soil” environment of 
the liver which is a frequent site of metastases from other tumors, especially 
those from the digestive tract like colorectal carcinomas.  
HCC is a hypervascular tumor, and is thought to be highly angiogenic.15,16
This thesis focused on the angiogenic status of liver tumors (not only HCC). In 
our studies, we did not find a robust pro-angiogenic status of HCC at 3 levels 
investigated: endothelial cell dynamics (at the cellular level), vessel maturation  
(at the vascular level), and VEGF / Angiopoietins / COX2 expression (at the 
molecular level).  
The literature often considers vascularity and angiogenesis to be 
synonymous. However, several issues can be raised which consider this as an 
unjustified simplification. Firstly, the resolution of imaging techniques like 
conventional angiography, computed tomographic angiography and magnetic 
resonance angiography is insufficient to delineate the microvessels which are 
the result of angiogenesis.17 Secondly, upregulation of VEGF expression in 
HCC is often evaluated in relation to hypervascularity on imaging techniques to 
find support for the correlation between angiogenesis and vascularity.18,19
VEGF in itself is not able to induce the angiogenic switch, but requires other 
growth factors, for instance Ang-2, to exert its action. Thirdly, the most pivotal 
changes in vascularization of HCC at the histological level is the presence of 
sinusoidal capillarization and the presence of unpaired arteries, and especially 
these characteristics did not (sinusoidal capillarization) or weakly (number of 
unpaired arteries) correlate with contrast enhancement in the arterial phase on 
dynamic computer tomography.20 Finally, tumor vessels in HCC are 
characterized by abnormal arterial-venous connections; especially 
arterioportal and arteriovenous shunts are often identified.21,22 These shunts, 
although characterized by large supplying vessels (hypervascularization), 
represent inefficient tumor angiogenesis because they “bypass” the tumor cells 
and thereby prevent exchange of oxygen and nutrients. Taken together, these 
radiological techniques can thus be regarded as reasonable markers of tumor 
blood flow but at most as indirect, surrogate, and thus unreliable markers of 
angiogenesis. Future new technical developments will hopefully more clearly 
delineate which of the many variables of dynamic imaging are most suited for 
reliable measurement of tumor angiogenesis.23
Also, in the benign primary hepatic tumors the studied angiogenic growth 
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factors imply that VEGF-A driven angiogenic sprouting is not happening in the 
tumors, and that remodeling, possibly through Ang-1/Tie-2 signaling, is 
stimulated. From this one can conclude that the vascular remodeling, guided 
by an altered vascular and sinusoidal milieu, could properly meet the 
requirements of the tumor’s growth and nutritional needs without robust 
neovessel formation.  
There is no extensive solid proof nor consensus to support the concept 
that HCC is highly angiogenic. Our data on low VEGF expression, the most 
extensively studied angio-gene in HCC, corroborate a few previously 
published studies reporting on the absence of upregulation of VEGF gene in 
HCC.24 On the other hand, ample studies reported the overexpression of 
VEGF in human HCC tissues by immunohistochemistry,19,25,26 which 
supported the notion that HCC is a highly angiogenic tumor. According to our 
experience, one should carefully interpret the expression of proteins using 
immunohistochemistry. As hepatocytes are a rich source of various proteins, it 
is easy to get non-specific staining. In our research, we found different patterns 
of VEGF-A, Ang-2, Tie-2 staining between immunostaining on paraffin and on 
frozen tissues. Immunostaining on paraffin sections showed that VEGF-A is 
abundant and diffusedly distributed in the cytoplasm of almost all hepatocytes 
and tumor cells, just like other studies have reported before.27 In contrast, 
using the frozen sections of the same cases, the VEGF-A expression was 
much less abundant and located mainly in the endothelial cells. As a growth 
factor, VEGF-A was not expected to be abundantly expressed like structural 
proteins. Moreover, the pattern of VEGF-A expression on frozen sections is 
more reasonable, and can be explained from the localization of VEGF-A in 
close proximity with its receptors on endothelial cells. The same observation 
was done with Ang-2 and Tie-2. Ang-2 expression is mainly restricted to 
endothelial cells. Immunostaining of Ang-2 on paraffin sections did not show 
this vascular restriction, while the immunostaining of frozen sections did show 
that Ang-2 is indeed localized mainly in endothelial cells.  Interestingly, in 
tissue adjacent to tumor or histological normal liver tissues a zonal distribution 
of Ang-2 in the center of liver lobule could be observed, which can be 
explained by the relative anoxic environment in the perivenular areas.  
 Phosphorylation of growth factor receptors and phospho-kinase activity 
analyses in situ may provide functional information on the activity of 
angiogenic factors. At present, however, the technology of 
anti-phospho-protein immunodetection is not extensively applied, mainly 
because of lack of special antibodies to phosphorylated proteins. Moreover, 
the existence of various phosphorylation sites in a single receptor or kinase 
protein can make interpretation of data rather cumbersome.  Our data 
suggests that the hepatic tumors do not have an overt manifestation of 
angiogenic activity according to the current model of angiogenic sprouting. In 
that model, Ang-2 acts as the dynamic factor that is overexpressed and 
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competes with Ang-1 for Tie-2 binding. As a consequence, Tie-2 is 
de-phosphorylated to destabilize the vasculature and sensitize the 
endothelium to VEGF induced proliferation. To further support the existence 
(or absence) of such a concept in human tumors, it is instrumental to create 
methods to study the phospho-Tie-2 status in tissue biopsies. Western Blot 
analysis of phospho-protein in whole tumor extracts or in Tie-2 
immunoprecipitated purified protein extracts is feasible nowadays. Yet, details 
on localization of its presence would provide important added value when 
considering the tumor and tumor vascular heterogeneity issue. Similarly, 
immunohistochemical detection of phospho-VEGFR-2 and other kinases 
proposed to be active during the angiogenic process would create new 
opportunities to zoom in on the molecular pathology of tumor associated 
neovascularization processes in human tumors. 
Other proangiogenesis factors in liver tumors 
The molecular repertoire that tumor cells can use to regulate angiogenesis 
is diverse and may alter for a given tumor type. Although VEGF has proven to 
be the most critical angiogenic factor identified to date, there are other 
pro-angiogenic factors, eg. FGFs, PDGF and EGF.28-31 Most human cancers 
can express several proangiogenic proteins.32-34 Placental growth factor 
(PlGF), a member of the VEGF family may primarily mediate arteriogenesis, 
the formation of collaterals from preexisting arterioles, but has also been 
associated with angiogenesis and was proposed as a potential therapeutic 
anti-angiogenic target.35 PDGF-BB and bFGF were recently described to have 
an important synergistic role in tumor neovascularization and metastasis, 
without any involvement of VEGF.36 So in the future, it is worthwhile to 
investigate other pro-angiogenic factors as potential mediators of vascular 
remodeling in HCC. 
Other mechanisms of tumor vascularization in liver tumors 
In recent years, additional mechanisms of tumor vascularization have been 
recognized, including recruitment of endothelial progenitor cells, vessel 
co-option, vasculogenic mimicry vessels and intussusceptive vascular 
growth.13,37 Vasculogenic mimicry was furthermore recently reported to be 
present in hepatocellular carcinoma and shown to be associated with tumor 
recurrence after orthotopic liver transplantation.38 And, like we pointed out in 
chapter 1, there is some proof to support that the tumor cells in liver (primary or 
metastatic tumors) may exploit pre-existing vessels for their growth.  
At present, we lack a vascular marker for (sinusoidal) endothelial co-option, 
and hence cannot test the hypothesis that HCC is nourished by vessels that 
are coopted instead of being created by angiogenic sprouting. Yet, the finding 
that HCC can grow in the absence of increased expression of VEGF and a 
destabilized Ang/Tie-2 phenotype puts forward an intriguing premise that the 
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permissive role of SEC may be a general feature for tumor growth in the liver. 
The recent observations that the expression of VEGF-A in primary colorectal 
carcinoma is higher than in colorectal carcinoma metastases in the liver39 and 
that primary pancreatic cancer expresses twice as much VEGF as compared 
to its metastasis in the liver40 are compelling indications that the liver niche 
indeed represents a microenvironment that can actively influence tumor 
growth characteristics. At present, however, nothing is known about how 
co-opted blood vessels differ from the normal vasculature and the possible 
implication for responsiveness/adaptation to anti-angiogenic therapy.41
Alterations of sinusoidal endothelial cell phenotype in various liver 
lesions
The liver is a special organ, receiving 15-20% of the cardiac output, in 
which approximately one-third from the hepatic artery (well oxygenated blood) 
and two-thirds from the portal vein (nutrient-rich blood from the digestive tract). 
The hepatic artery and portal vein both drain into the hepatic sinusoids, which 
represent the capillary network in the liver.42 Regenerative and dysplastic 
nodules in liver have a blood supply predominant from the portal vein, and lack 
contrast uptake in the arterial phase in contrast-enhanced liver imaging. Upon 
dysplastic nodules transition into overt HCC, the vessel pattern sharply 
changes and arterial supply is predominant.43 From early to fully malignant 
noduIar lesions in liver, the number of unpaired arteries increases. The 
unpaired arteries refer to arteries not accompanied by bile ducts as in portal 
tracts of normal liver, and can be highlighted with CD34 and SMA 
immunostaining.44 Scanning electron microscopic imaging shows tumor 
vessels with irregular diameters and abnormal branching pattern.45
Hepatic sinusoidal endothelial cells (SECs) are discontinuous and possess 
fenestrations, and also display gaps and lack an organized basement 
membrane.46 During liver organogenesis, an early structural differentiation of 
sinusoids, occurring from 5 to 12 weeks of gestation, was characterized by the 
loss of continuous endothelial cell markers (CD-31, CD34) and a reduction in 
the peri-sinusoidal amount of laminin and in the deposition of tenascin, 
fibronectin, and thrombospondin. A later functional differentiation was 
characterized by the acquisition of the markers of adult sinusoidal endothelial 
cells (CD4, ICAM-1, CD32, and CD14), during 10-20 weeks of gestation. The 
typical ultrastructures of SECs, including cytoplasmic fenestrations, are not 
acquired before 17 gestational weeks.47
FNH presented a sinusoidal pattern of endothelial cell differentiation. All 
HCC presented a continuous pattern of endothelial cell differentiation. In 
hepatocellular adenomas, the intra-tumoral vascular phenotype was 
heterogeneous, with 50% presenting a sinusoidal pattern, 19.5% presenting a 
continuous pattern and 30.5% showing a mixed pattern.48
As pointed by Frachon S et al., there are two possible mechanisms to 
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explain the alterations of the vascular phenotype. One hypothesis states that 
tumor-associated capillary vessels are neo-vessels produced through a 
process of tumor angiogenesis. Another hypothesis is that the phenotypic 
changes indicate an abnormal differentiation of pre-existing sinusoids.49 In 
other words, increasing CD34 expression by endothelial cells might represent 
a bystander effect of changing influences from adjacent cells or growth factors. 
The liver sinusoids may represent a specialized vascular bed that preferentially 
facilitates pathology related demands by vascular remodeling via other 
mechanisms than angiogenic sprouting.  We have observed that in the border 
of HCC with adjacent liver, the adjacent non-tumorous liver parenchyma 
shows a very faint staining of CD34 with a gradual increase in staining intensity 
towards the tumor (see chapter 2). Moreover, CD34 staining is not uniform as 
both CD34 positive and CD34 negative segments of vessels can be 
encountered especially in the periphery of HCC. Today, we cannot test those 
hypotheses. However, investigations of isolated endothelial cells or tumor 
vessels on the aspect of angiogenic associated factors will be helpful to 
elucidate microenvironments in which endothelial cells live, and maybe provide 
a potential target for therapeutically targeting tumor vasculatures in HCC.
Isolation of intra-tumor endothelial cells for detailed angiogenesis 
studies 
To obtain a full angiogenic profile of tumor endothelial cells it is essential to 
purify the cells from the tumor tissue, as the intra-tumor endothelial cells 
represent only a small fraction of cells in tumor tissue. Results of analysis of 
whole tissue samples are usually determined by the major cell type and may 
mask biologically relevant and important changes present in endothelium. For 
this purpose, St. Croix et al. isolated endothelial cells by enzymatic digestion of 
tumor tissue, followed by sorting with magnetic beads. They next used SAGE 
(serial analysis of gene expression) to compare gene expression patterns of 
endothelial cells isolated from the blood vessel of normal resting tissues, 
tumors, and regenerating liver. They found striking differences between 
physiological and pathological angiogenesis, and confirmed their findings by 
real time RT-PCR, in situ hybridization, immunostaining and immunoblotting.50
Isolation of endothelial cells by enzymatic digestion and sorting by magnetic 
beads, influence endothelial cell behavior in various ways.12 In addition, one 
looses information on the original location of the endothelial cells in the (tumor) 
tissue, and hence information that may be of essential importance in the light 
of tumor vascular heterogeneity. 
The development of laser-based tissue microdissection systems now 
allows for rapid acquisition of specific morphologically and/or phenotypically 
distinct types of cells for a number of molecular analyses.51 In cancer research, 
laser microdissection has been most extensively used to get tumor cells for 
subsequent analysis. The endothelial cells are small, and difficult to identify 
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from other cells in histologically stained tissue. Combined with immunostaining 
for endothelial or angiogenic markers, laser capture microdissection can be 
used to get endothelial cells from tissues. Immunohistochemistry-guided LCM 
has the advantage of capturing ECs from their natural (patho) physiological 
microenvironment with maintenance of information on localization and 
associated pathology. Using immuno- laser capture microdissection  to get 
endothelial cells and subsequent genome-wide transcriptional profiling, 
Buckanovich et al. identified genes that were differentially expressed between 
vascular cells from human epithelial ovarian cancer and healthy ovaries.52
Similarly, Bhati et al performed rapid immunohistochemistry using anti-factor 
VIII-related antibodies on sections of frozen human luminal-A breast tumors 
and normal breast, followed by laser capture microdissection of vascular cells. 
They identified 1176 genes that were differentially expressed between tumor 
and normal vascular cells, 55 had a greater than fourfold increased expression 
level.53
To further detail on the molecular status of the tumor vasculature in liver 
tumors, the immuno- laser capture microdissection technique is highly suited 
as a method to isolate endothelium from HCC, adjacent non-tumor tissues, 
cirrhotic liver and benign liver tumors, and will be pursued in our laboratory in 
the coming years. Whether the read-out will be quantitative RT-PCR, which 
represents a biased approach that analyses pre-destined sets of genes, or a 
genome wide microarray study, will depend on the yield of RNA from the 
dissected samples and the advances in technologies to amplify the RNA 
without disturbing the high abundant / low abundant gene profiles of the RNA. 
Using this approach for HCC and their healthy control tissues, we hope to be 
able in the future to identify molecular markers that can assist in further 
unraveling of the actual status of tumor vasculature, for use in daily 
pathological practice and beyond. 
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Nederlandse samenvatting 
Kwaadaardige aandoeningen in de lever zijn onder te verdelen in 
primaire en secundaire tumoren. Secundaire tumoren (metastasen) ontstaan 
doordat kankercellen vanuit een kankergezwel elders in het lichaam 
(bijvoorbeeld dikke darmkanker) naar de lever zijn versleept en zich daar 
hebben gevestigd en ontwikkeld. Primaire levertumoren ontwikkelen zich in de 
lever zelf en ontstaan uit één van de in de lever voorkomende celtypen. De 
meest frequent voorkomende vorm hiervan is het hepatocellulair carcinoom of 
HCC. Deze vorm van kanker staat wereldwijd qua incidentie op de vijfde plaats 
en staat op de derde plaats wat betreft de oorzaak van sterfte aan kanker1.
Meestal ontstaat HCC in een lever die al door een chronische leverziekte is 
aangedaan en waar bindweefselvorming tot levercirrose heeft geleid. De 
slechte prognose van het HCC is het gevolg van het gebrek aan adequate 
behandelmethoden, niet in de laatste plaats door de beperkingen die de 
levercirrose zelf veroorzaakt.  
Tegenwoordig wordt angiogenese, de vorming van nieuwe bloedvaten uit 
bestaande bloedvaten, gezien als een belangrijk nieuw aangrijpingspunt voor 
therapie van deze tumoren. Het verkrijgen van inzicht in de cellulaire en 
moleculaire processen die ten grondslag liggen aan angiogenese in humane 
tumoren is van essentieel belang om geneesmiddelen te ontwikkelen en 
effectieve therapeutische behandelschema’s te maken. 
 Tot op heden is angiogenese in levertumoren bij patiënten niet in detail 
onderzocht. Bovendien blijkt het milieu waar het HCC in ontstaat van groot 
belang voor het gedrag van het HCC: is het HCC ontstaan in een verder niet 
zieke (normale) lever of is het HCC ontstaan in een chronisch zieke, cirrotische 
lever? Omdat moleculaire controle van angiogenese in belangrijke mate wordt 
beïnvloed door de omgeving waarin de nieuwe bloedvatvorming zich voordoet, 
doet de vraag zich voor in hoeverre de angiogene status van HCC in een 
verder normale lever verschilt van die van HCC in een cirrotische lever. Naast 
HCC komen er in de lever ook goedaardige tumoren voor. Dit betreft de 
zogenaamde focale nodulaire hyperplasie (FNH) en de hepatocellulaire 
adenomen (HCA). FNH omvat 8% van alle primaire levertumoren en is de 
tweede meest voorkomende goedaardige tumor naast hemangiomen2.
Hepatocellulaire adenomen zijn zeldzaam maar een overgang naar een 
kwaadaardige groei is beschreven3. Net als voor HCC is voor deze 
goedaardige tumoren de kennis omtrent de nieuwe bloedvatvorming nog 
beperkt.
 Het doel van dit promotieonderzoek was de cellulaire en moleculaire 
controle te bestuderen van nieuwe bloedvatvorming in kwaadaardige en 
goedaardige levertumoren. We hebben hiertoe de doorbloeding, de activatie- 
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en delingsstatus van de endotheelcellen die de tumorbloedvaten bekleden, de 
productie van factoren betrokken bij nieuwe bloedvatvorming, en de mate van 
bloedvatmaturatie bestudeerd. Hierbij hebben we ons met name gericht op 
genexpressie en de bijbehorende produktie van eiwitten waarvan op dit 
moment wordt gedacht dat ze een essentiële rol spelen in de initiatie van 
bloedvatnieuwvorming. 
 In hoofdstuk 2 zijn in HCC’s in cirrotische en normale levers verschillende 
parameters gemeten die de endotheelceldynamiek weergeven als indirecte 
indicatoren van angiogene activiteit: endotheelceldeling en apoptose, 
microvasculaire dichtheid (MVD), en bloedvatmaturatie/stabiliteit in de vorm 
van pericytenbekleding. We hebben deze uitkomsten gecorreleerd met tumor 
vascularisatie zoals dat zichtbaar wordt gemaakt met een speciale vorm van 
CT beeldvorming, de zogenaamde dynamisch contrast versterkte CT. De 
microvasculaire dichtheid wordt gezien als een maat voor bloedvatvorming en 
om die reden hebben we de invloed van MVD op de prognose van patiënten 
met een HCC onderzocht. We vonden dat in beide condities van tumorgroei 
(HCC in normale en in cirrotische levers) de endotheelcelproliferatie en 
frequentie van apoptose in de tumorbloedvaten laag zijn, en dat de meeste 
bloedvaten omgeven zijn door pericyten, wat een grote mate van 
bloedvatstabiliteit suggereert. De MVD bleek bovendien niet gecorreleerd met 
de op de CT scan gemeten bloedtoevoer maar was wel negatief gecorreleerd 
met de bloedafvoer. In HCC in niet-cirrotische levers, waarvoor de patiënten 
werden behandeld middels partiële leverresectie, was een hogere MVD 
maatgevend voor een betere prognose. Parameters van 
endotheelceldynamiek in deze tumoren gaven vooral een beeld van rustige, 
mature tumorbloedvaten. 
 Gebaseerd op de uitkomsten van de studie in hoofdstuk 2, kwamen we tot 
de hypothese dat angiogenese niet een prominente eigenschap van klinisch 
detecteerbare HCC’s is. In hoofdstuk 3 hebben we daartoe in humane HCC 
de gen- en eiwitexpressie geanalyseerd van de moleculen die verantwoordelijk 
worden geacht voor het initiëren van de eerste fase van de angiogenese. De 
moleculen die we hebben onderzocht zijn VEGF (Vascular Endothelial Growth 
Factor) en zijn twee receptoren VEGFR-1 en -R2, en de Angiopoietines Ang-1 
en Ang-2, en hun receptor Tie-2. We hebben naast kwantitatieve RT-PCR om 
mRNA niveaus te meten, eiwitkwantificatie gedaan met Western blot analyse 
en lokalisatie van eiwitexpressie op weefsel niveau gedetecteerd middels 
immunohistologische analyse. We vergeleken de uitkomsten met analyses van 
dezelfde genen en eiwitten in niercel-carcinoom (RCC), een tumor-type dat als 
gevolg van een genetische mutatie sterk angiogeen is en als één van de 
meest bloedvatrijke tumoren in het menselijk lichaam wordt gezien. HCC in 
een normale lever en HCC in een cirrotische lever brachten de groeifactor 
VEGF-A in dezelfde mate tot expressie als samples van een normale, 
gezonde lever zonder tumor. In beide tumortypen was de Ang-1 genexpressie 
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